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Abstract 
 
Uterine fibroids are the most common tumour of the reproductive tract in women 
of reproductive age. Although they are benign tumours that are often 
asymptomatic, they may cause debilitating symptoms in many women, such as 
abnormal uterine bleeding, abdominal pain, increased abdominal girth, urinary 
frequency, constipation, pregnancy loss, dyspareunia, and in some cases 
infertility.  
 
Several approaches are available for the treatment of uterine fibroids. These 
include pharmacologic options, such as hormonal therapies and gonadotropin-
releasing hormone agonists; surgical approaches, such as hysterectomy, 
myomectomy; myolysis, laparoscopic uterine artery occlusion, uterine artery 
embolisation and magnetic resonance imaging-guided focused ultrasound surgery. 
The choice of approach may be dictated by factors such as the patient’s desire to 
become pregnant in the future, the importance of uterine preservation, symptom 
severity, and tumour characteristics. There is however, no widely agreed 
therapeutic strategy. There is a widespread view that hysterectomy is overused in 
the UK; the Chief Medical Officer in his annual report ‘On the state of public 
health’ in 2005, highlighted that hysterectomy in younger women is associated 
with complications, hospital stays, procedure-related interference with normal life 
and is costly. In addition he outlined the need to reduce the number of 
hysterectomies.  This, along with the change in cultural attitudes amongst patients, 
who are becoming increasingly reluctant to undergo these conventional invasive 
procedures, has increased the need for new treatment options.  
 
Ideally new treatment options for uterine fibroids would be minimally invasive, 
have long-term data demonstrating efficacy and safety, have minimal or no 
incidence of fibroid recurrence, be easy to perform, preserve fertility, and be cost 
effective. New treatment approaches are under investigation, with the goals of 
being effective, safe, and less invasive.  
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MRgFUS is a non-invasive thermo-ablative hybrid technique which uses both MR 
and ultrasound to destroy tumours. It is an outpatient procedure, which avoids the 
need for an anaesthetic, has a short recovery period, and is uterine sparing. 
 
The main objective of this work was to set out the rationale for using Magnetic 
Resonance guided Focused Ultrasound Surgery (MRgFUS) for the treatment of 
uterine fibroids. In order to achieve this aim, four main bodies of work are 
necessary;  
1) Identifying patient selection criteria and investigating mitigating 
techniques to increase the pool of women for whom this treatment can be 
offered. 
2) Investigating a method designed to overcome the problem of safely 
treating women with abdominal scars for whom this treatment can cause 
potential morbidity. 
3) Investigating the potentiality of using MRgFUS to prolong the tumour 
shrinkage effect of GnRH analogue injections.  
4) Investigating the safety of MRgFUS in treating symptomatic women who 
wish to preserve fertility. 
  
Results: the first aim of this project was to identify patient selection criteria and to 
investigate methods to widen the selection criteria. In our retrospective review it 
was found that 74% of women presenting were deemed technically suitable to 
proceed with treatment and several mitigating techniques that solved current 
technical difficulties were identified and allowed for less restrictive MRgFUS 
selection criteria for treatment of symptomatic uterine fibroids.  These less 
restrictive criteria are expected to expand the pool of patients for whom MRgFUS 
is a viable treatment option for uterine fibroid symptoms. 
 
The second aim was to identify a method of overcoming the problem of treating 
women with previous abdominal scars safely. We identified a unique method of 
highlighting the scar by painting it with a paramagnetic iron oxide material which 
clearly outlined the scar on MR scanning allowing complete avoidance of the scar 
using MR guidance. In this small pilot study, all women were treated safely with 
no skin burns. 
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The third aim of this project looked at the potentiality of prolonging the shrinkage 
effect of GnRH analogues by following a course of 3 injections with MRgFUS 
treatment. In this prospective study of fifty women, there was a 50% reduction in 
the mean symptoms severity score at 6 months which was maintained for 24 
months post treatment. There was an average reduction in target fibroid volume 
which was maintained for 24 months. 
The final aim of the project was to investigate the safety of using MRgFUS as a 
treatment option for those women who wished to preserve their fertility. In this 
multicentre international study, One hundred and sixteen women were recruited 
from five centres. There were sixty four reported pregnancies in Sixty one 
women, with 30 completed deliveries.  There were no reported cases of uterine 
rupture, premature labour, abnormal placentation or placental abruption. 
 
Conclusion: There is a growing body of data from clinical trials and more than 
four years of clinical experience to validate the safety and efficacy of MRgFUS 
for the treatment of uterine fibroids. MRgFUS is a totally non-invasive outpatient 
procedure that is not associated with the typical surgical risks of bleeding, 
infection and has minimal recovery time. Additionally, the procedure allows 
women to address their symptoms whilst preserving the uterus.   Consequently, 
MRgFUS is an alternative treatment option for suitable patients who have refused 
other interventions due to concerns about lost productivity, risks of surgical 
complications or future fertility 
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1.1.1Definition and Introduction 
 
Uterine leiomyomata are the most frequent myometrial disorders and the most 
common pelvic tumour in women. Although they are commonly referred to as 
fibroids, the tumour consists of uterine smooth-muscle tissue and is encased in 
fibrous extracellular matrix (Stewart 2001). In some cases, fibroids appear to 
originate from smooth-muscle cells of the uterine blood vessels (Cramer and Patel 
1990). 
 
Macroscopically, these clonal tumors are firm, round, or oval-shaped. 
Microscopically, they are composed of smooth-muscle bundles in a whirl-like 
pattern, well circumscribed but not encapsulated. Of importance in therapy, they 
are often highly vascular. They can be singular, but generally, there are multiple 
fibroids in the same uterus varying in dimensions and location.  
 
A common misconception is that of malignant transformation of fibroids. 
Sarcomas are almost certainly not the result of malignant transformation of 
myomas. Levy et al in their article on cytogenetic analysis state that myomas and 
leiomyosarcomas have different chromosomal abnormalities, and that 
transformation from myoma to leiomyosarcoma has never been confirmed (Levy, 
Mukherjee et al. 2000). 
 
 Eighty percent of women have myomas found at hysterectomy, so it is not 
surprising that a sarcoma arises in a uterus with myomas coincidentally present. A 
study by Parker et al identified only 1 out of 371 women admitted with rapidly 
growing myomas had a sarcoma, confirming this as an exceedingly rare 
association (Parker, Fu et al. 1994). 
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1.1.2 Incidence and Risk factors 
 
The prevalence of clinically significant fibroids peaks toward the end of a 
woman’s reproductive cycle, in her peri-menopausal years, and declines after 
menopause (Flake, Andersen et al. 2003).  
Although most women with uterine fibroids do not seek therapy, 20% to 25% of 
women in the reproductive age do have sufficiently significant symptoms caused 
by fibroids to cause her to seek and warrant (Buttram and Reiter 1981). Genetic 
predisposition seems to contribute. Fibroids are particularly common in Afro-
Caribbean populations with a three-fold increase in incidence compared to 
Caucasian populations. Also, the clinical disease of these women is more severe 
(Kjerulff, Langenberg et al. 1996). 
 
Although uterine leiomyomata affect the reproductive health and well-being of 
approximately 25% of premenopausal women, risk factors are poorly understood. 
Elevated adult body mass index is associated with a modest increased risk of 
uterine leiomyomata among premenopausal women (Luoto, Kaprio et al. 2000), 
as is a familial tendency to develop fibroids. Parity reduces risk, and the risk 
reduces with the number of births (Lethaby and Vollenhoven 2002). Dietary 
associations with fibroids have been investigated and the presence of fibroids is 
associated with beef and ham consumption, whereas high intake of green 
vegetables seems to have a protective effect (Chiaffarino, Parazzini et al. 1999).  
 
Elevated diastolic blood pressure may increase fibroid risk through uterine smooth 
muscle injury, not unlike atherosclerosis. Boynton-Jarret et al prospectively 
examined the relation between diastolic blood pressure and incidence of clinically 
detected leiomyomata. The sample included 104,233 premenopausal nurses from 
14 US states enrolled in the Nurses’ Health Study II. Participants, aged 25–42 
years, had intact uteri and no history of cancer or fibroids at enrolment in 1989. 
During the 827,348 woman-years of follow-up (1989–1999), 7,466 incident 
diagnoses of uterine leiomyomata confirmed by ultrasound or hysterectomy, were 
reported. With adjustment for age, ethnicity, body mass index, and reproductive 
history, it was concluded that elevated blood pressure has an independent, positive 
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association with risk for clinically detected uterine leiomyomata among 
premenopausal women (Boynton-Jarrett, Rich-Edwards et al. 2005). Investigating 
this association may suggest possible pathways to prevent fibroids.  
 
Several correlative risk factors were derived from the Black Women’s Health 
Study, a U.S. prospective cohort study of black women who completed biannual 
mailed health questionnaires. From 1997 through 2001, 21,506 premenopausal 
women with intact uteri and no prior diagnosis of uterine leiomyomata were 
followed. It concluded that BMI and weight gain exhibited a complex relation 
with risk of uterine leiomyomata in the Black Women’s Health Study. The 
association with BMI was an inverse J-shaped curve and findings were stronger in 
parous women. Weight gain was positively associated with risk among parous 
women only (Wise, Palmer et al. 2005) 
 
In US black women, risk of uterine leiomyomata was positively associated with 
current consumption of alcohol, particularly beer. Cigarette smoking and caffeine 
consumption were unrelated to risk overall. During 76,711 person years of follow-
up, 2,279 new cases of ultrasound- or hysterectomy-confirmed uterine 
leiomyomata were self-reported. After adjustment for age, body mass index, 
smoking, alcohol intake, and other reproductive covariates, the risk of ultrasound- 
or hysterectomy-confirmed leiomyomata was inversely associated with age at 
menarche, parity, and age at first birth and positively associated with years since 
last birth. Overweight or obesity appeared to attenuate the inverse association 
between parity and uterine leiomyomata (Wise, Palmer et al. 2004).  
 
Current use of progestin-only injectables was inversely associated with risk. No 
consistent patterns were observed for other forms of hormonal contraception. 
Reproductive history is an important determinant of leiomyomata risk in 
premenopausal US Black women. Progestin-only injectables may reduce risk 
(Wise, Palmer et al. 2004). 
 
Fibroids decrease in size during menopause and under other hypo-oestrogenic 
conditions and also after down-regulation treatment with gonadotrophin-releasing 
hormone (GnRH) agonists (West, Lumsden et al. 1992).  This supports the fact 
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that fibroids are steroid-dependant tumours. Although oestrogen has been 
implicated as the important hormone, evidence has been found to show that 
progesterone also plays a role in the growth of fibroids. It is controversial whether 
Oestrogen or progesterone is the more important influence (Sankaran and 
Manyonda 2008). 
 
 
1.1.3 Classification 
 
Fibroids are classified by their location (see figure 1), which affects the symptoms 
they may cause and how they can be treated. Leiomyomas may be subserosal, 
submucosal, or intramural; however, most fibroids are combinations. Subserosal 
fibroids are on the external surface of the uterus, the uterine serosa and can be 
sessile or pedunculated. This type of fibroid is the easiest to remove by 
laparoscopy. Submucous myomas are in the inner aspect of the myometrium, 
immediately below the endometrium. These fibroids often pouch into the 
endometrial cavity and can be removed by hysteroscopic resection. Intramural 
leiomyomas predominantly occur within the thick myometrial layer of the uterus. 
They may distort the uterine cavity or cause an irregular external uterine contour. 
Many of these do not cause symptoms unless they become quite large. (See figure 
2)  
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Chapter 1 fig. 1. An artistic impression of the uterus showing the various 
classifications of fibroids. 
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 Chapter 1 fig. 2. A T2 weighted coronal image of a massive fibroid clearly 
causing compression of retro-peritoneal structures (source: St Mary’s 
Radiology department). 
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1.1.4 Symptoms 
 
Fibroids can present with a variety of symptoms depending on their size, location, 
and the reproductive status of the woman. Uterine fibroids can cause abnormal 
uterine bleeding, pain and pelvic pressure symptoms (Buttram and Reiter 1981). 
The impact of uterine leiomyomata on reproduction is more controversial and will 
be discussed further in this thesis, however it will be addressed here briefly for 
completeness. 
 
Bleeding  
The most common kind of abnormal bleeding associated with leiomyomas is 
menorrhagia or hyper menorrhoea, prolonged or excessively heavy menstruation 
i.e. an increase in the amount of blood loss per month (Stewart 2001). The heavy 
bleeding frequently results in iron deficiency anaemia, and the frequent change of 
tampons or pads may cause a significant disruption to daily activities, social 
isolation and loss of productive time (Parker 2007) 
The exact mechanism by which fibroids cause abnormal bleeding is unknown, 
however some theories include: 
x Increased endometrial surface area  (Stovall 2001) 
x Increased vascularity of the uterus 
x Interference with normal uterine contractility 
x Endometrial ulceration over submucuous leiomyomas, which could also 
cause inter-menstrual bleeding and 
x Compression of the venous plexus within the myometrium, leading to 
endometrial venule ectasia which results in the congestion of myometrium 
and endometrium leading to profuse menstrual bleeding (Farrer-Brown, 
Beilby et al. 1971) 
 
It must be remembered however that women presenting with menorrhagia must be 
investigated fully to exclude other endometrial pathologies, as this symptom is not 
specific to myomas. 
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Pelvic pressure  
Pelvic pressure is due to mass effects from the fibroid and enlargement of the 
uterus. The pelvic and abdominal discomfort is analogous often to the discomfort 
women experience during pregnancy. These symptoms develop insidiously and 
are often attributed to simply putting on weight, especially if there are no 
associated changes in menstrual pattern. the location of pressure is related to the 
location of the fibroids, thus as the tumour grows neighbouring structures can be 
compressed by the fibroid and this may lead to difficulty with urination when 
there is an anterior fibroid or problems with defecation and dyspareunia when 
there is a posterior wall fibroid.  
 
Reproductive dysfunction 
It is estimated that approximately 30% of women have a fibroid(s) by the age of 
30 years and is the current trend in developed countries, women are looking to 
start their family in their 30s or later; as such fibroids are frequently found in 
association with pregnancy (Bukulmez and Doody 2006). The vast majority of 
women have successful pregnancies, it is therefore reasonable to suggest that the 
majority of fibroids do not have an adverse effect on pregnancy. While this is 
likely to be the case, depending on their size, number and location, fibroids may 
result in a distortion of uterine anatomy, thereby interfering with normal uterine 
physiology. It is therefore logical to say that in some cases, fibroids could indeed 
have an adverse effect on reproductive function. It has been suggested that this 
could include sub-fertility, miscarriage and later pregnancy complications, 
including pain (red degeneration), premature rupture of membranes, pre-term 
labour, placental abruption, mal-presentations, unstable lie and increased 
operative deliveries. 
 
Acute pain 
Acute pain is rare, but can occur in situations where there is degeneration of the 
fibroid due to an insufficient blood supply; so called red degeneration, which 
occurs during a pregnancy. Uterine myomas as large as 100 lbs have been 
reported. These large myomas may outgrow their blood supply, leading to 
ischaemia and necrosis within the tumour. This degeneration is usually associated 
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with severe acute pain which may necessitate surgical exploration (Bukulmez and 
Doody 2006). Such large myomas can also be expected to cause respiratory 
compromise (Stovall 2001). Acute pain may also be due to torsion of a 
pedunculated fibroid or to cervical dilatation where a submucous fibroid extrudes 
through the uterus. Pain can also occur when the uterus with the fibroid becomes 
incarcerated within the pelvis (Phelan 1995). Rarely, myomas in the broad 
ligament may cause unilateral lower abdominal pain or sciatic nerve pain (Stovall 
2001). Another rare cause of acute pain and collapse can be caused by the 
spontaneous rupture of a superficial fibroid vessel, leading to a surgical 
emergency. There are however, only approximately twenty such reported cases in 
the literature (Sehgal and Haskins 1960). 
It is important to emphasise, however, that pain is not a common presenting 
feature of fibroids, and as such other pathologies such as ectopic pregnancy, 
rupture/torsion of an ovarian cyst must be considered in any women with 
identifiable myomas who experiences acute abdominal pain.  
 
1.1.5 Diagnosis 
 
Suspicion of a diagnosis of fibroid is made when a patient presents with a gradual 
increase in the size of their abdomen, heavy but regular periods and a negative 
pregnancy test. Other causes for an increased abdominal girth include; 
adenomyosis, ovarian cysts/ovarian neoplasms or non-gynaecological causes. It is 
difficult to differentiate between these simply on abdominal palpation, and an 
ultrasound (usually transvaginally) can confirm the diagnosis and exclude other 
conditions (see figure 3). Unfortunately although very sensitive for the detection 
of bulky enlarged uteri, ultrasound is not very specific for the diagnosis or precise 
location of fibroids. 
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Chapter 1 fig.3. An ultrasound image of a fibroid. Although sensitive for 
detection of masses, ultrasound is not very specific for the diagnosis 
(source St Mary’s Radiology department archives) 
 
Magnetic Resonance Imaging (MRI) has gained widespread use and popularity 
for use in pelvic imaging and in gynaecology. It is non-invasive and safe, with no 
radiation effects, especially important for younger women. The multi-planar 
sequences allow differentiation of the substructure of the uterus, cervix, vagina 
and ovaries (see figure 4). 
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Chapter 1 fig.4. MRI of normal uterus. The uterus is anteverted (1) the 
endometrial cavity (2), cervix (3) and vagina (4) are all clearly seen 
(source St Mary’s radiology department archives). 
 
It allows the radiologist to differentiate uterine anatomy and reliably localises, 
with precision, pelvic pathology. The routine use of both T1 and T2 –weighted 
(T1W and T2W) sequences, before and after the injection of i.v gadolinium, 
allows for optimization of the inherent tissue contrast available with MRI. It is 
uniquely able to characterise soft tissues with these sequences and can provide 
precise diagnoses for many forms of abnormalities. 
 
This has special advantages for imaging of fibroids. The first and foremost one is 
to confirm the diagnosis. There are many different types of fibroids, clinically and 
pathologically, with a broad range of features and so not surprisingly, there are 
variations in their location and appearance on MRI (see figure 5).  
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Chapter 1 fig.5.  MRI of pelvis showing enlarged uterus with multiple 
fibroids, intra-mural (1), sub-serosal (2) and pedunculated(3) types. 
(source: St Mary’s radiology department). 
 
Magnetic Resonance (MR) allows characterisation of the fibroids; with accurate 
size and volume measurement, the tissue can also be characterised into hyper-
intense or hypo-intense when compared to the myometrium, this gives an 
indication as to how vascular the fibroid is (see figure 6). 
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Chapter 1 fig.6. A T2 weighted sagittal image showing a large hyper-
intense anterior wall intramural fibroid (Source: St Mary’s Radiology 
department). 
 
By using i.v. contrast, the perfusion and therefore presence of necrosis and 
degeneration can be determined (See figure 7). 
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Chapter 1 fig.7. A T2 weighted sagittal image of the treated fibroid on the 
left. An IV contrast enhanced image of the same fibroid on the right 
showing non-perfusion (outlined in red) hence necrosis of the treated 
fibroid. (Source: St Mary’s radiology department). 
                                   
The ability to classify tissue on MRI is based upon a multi-parametric analysis of 
all the sequences with T1, T2, T1 fat-suppressed, and i.v. contrast-enhanced 
sequences all playing critical roles. The T2W images first allow location and 
diagnosis of fibroids as described above. The MR signal on any of the sequences 
can be iso-intense and higher or lower than skeletal muscle. IV contrast can 
determine the solid or cystic/necrotic nature of the tissue and if done in rapid 
bolus fashion can help with perfusion analysis. The gradient echo technique used 
for gadolinium imaging can also be used to detect fat or calcium. The ‘classic’ 
fibroid is a well-circumscribed mass with low signal intensity on all pulse 
sequences. On T2W MRI exams, uterine fibroids are usually easily identifiable. 
Adenomyosis may give a very similar appearance on MR, however the mass is 
usually less defined and more diffuse (See image 8). 
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Chapter1 fig. 8. Sagittal MR image of a uterus with extensive 
adenomyosis. A gynaecological condition which is often misdiagnosed as 
uterine fibroids on ultrasound scan. The superior imaging capacity of MR 
allows for easy differentiation. (Courtesy of www.ufeinfo.com). 
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1.1.6 Treatment  
 
Uterine myomas can generally be managed expectantly unless they cause 
symptoms. Several approaches are available for the management of symptomatic 
tumours. The approach will be dictated by factors such as the patient’s desire to 
become pregnant in the future, the importance of uterine preservation, symptom 
severity, and tumour characteristics.  
 
Pharmacological options 
 
At present, pharmacological therapies are only used for short-term therapy 
because of the significant risks with long-term therapy, or lack of evidence 
regarding the benefits and risks of long-term therapy with the newer medical 
agents. A number of options are available, including hormonal therapies, such as 
gonadotrophin-releasing hormone analogues (GnRHa) agonists/antagonists, 
aromatase inhibitors selective oestrogen receptor modulators (SERM), anti-
progestins (mifipristone and asnoprisnil) and cabergoline. The combined oral 
contraceptive and progestins are used to manage bleeding but no evidence 
supports their efficacy in actually influencing myoma size. 
 
GnRH analogues 
First synthesised in the 1970s, GnRHa has been used extensively in clinical 
medicine, there are over 2000 analogues with both antagonistic and agonistic 
properties. Used in the treatment of hormone dependent tumours in other clinical 
areas such as for prostatic cancer, in gynaecological practice they are used for a 
variety of conditions such as endometriosis, hirsituism, dysfunctional uterine 
bleeding, premenstrual syndrome, assisted reproduction and fibroids. They were 
first used for uterine fibroids in the late 1980s. GnRHa undoubtedly induce fibroid 
tumour shrinkage, the degree of which has been shown to be inversely 
proportional to the percentage of cells that are oestrogen positive, thus implicating 
oestrogen as a major effector of tumour growth and its reduction as the central 
mechanism of fibroid shrinkage with GnRHa therapy. Continuous administration 
of a GnRH agonist acts to produce hypo-menorrhoea or amenorrhoea and can 
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reduce the size of myomas (Chillik and Acosta 2001). Currently limitations are 
placed on duration of use due to risk of significant bone loss from the profound 
oestrogen deficiency created (Chavez and Stewart 2001). Co-administration with 
agents such as oestradiol, norethindrone,raloxifene, and tibolone appears to 
prevent GnRH agonist related bone loss in pre-menopausal women with uterine 
fibroids (Palomba, Orio et al. 2002). Calcified fibroids appear to be resistant to 
therapy with GnRH agonists (Chavez and Stewart 2001). 
 
 
Selective oestrogen receptor modulators 
Best known for their use in the treatment of oestrogen receptor positive breast 
cancer, SERMs are non-steroidal oestrogen receptor ligands that act as oestrogens 
in some tissues while blocking oestrogen action in others. 
Any molecule that blocks oestrogen activity has the potential for therapeutic 
activity against fibroids, since oestrogen is known to influence fibroid growth. 
SERMs are therefore within this category of molecule. A 60 mg daily dose of 
Raloxifene has been shown to reduce fibroid volume for up to one year, but only 
in post-menopausal women (Palomba, Sammartino et al. 2001). Pre-menopausal 
women given the same treatment did not respond even when higher doses (180 
mg/day) of raloxifene were used (Palomba, Orio et al. 2002). The explanation 
may simply be that raolxifene is able to counteract the low concentrations of 
background oestradiol seen in post-menopausal women (Marsh and Bulun 2006). 
Side effects of raloxifene include; hot flushes, increased appetite, weight gain, 
gastralgia, dry skin and venous thrombo-embolism (Jirecek, Lee et al. 2004). 
 
Aromatase inhibitors 
Aromatase inhibitors markedly suppress plasma oestrogen levels in 
postmenopausal women by inhibiting or inactivating aromatase, the enzyme 
which catalyses the synthesis of oestrogens from androgenic substances such as 
androstenedione (Smith and Dowsett 2003). Leiomyoma cells and subcutaneous 
fat cells express aromatase, and are therefore able to synthesise oestrogen. This 
observation may explain why fibroids do not always regress in post-menopausal 
women, and also suggests a possible therapeutic role for aromatase inhibitors in 
the treatment of symptomatic fibroids in premenopausal and menopausal women 
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(Shozu, Murakami et al. 2004). To date, the use of aromatase inhibitors for the 
treatment of fibroid disease is confined to case reports. Kanuitz described the 
successful use of Anastrozole, a third-generation non-steroidal aromatase 
inhibitor, in treating uterine bleeding associated with fibroids in an obese post-
menopausal woman (Kaunitz 2007). Anastrozole use was associated with a 
reduction in the size of the woman’s dominant fibroid, thinning of her 
endometrium and cessation of bleeding. Japanese investigators have reported the 
successful use of an aromatase inhibitor, Fadrozole, in reducing the dimensions of 
a fibroid tumour causing urinary retention in a peri-menopausal woman. They 
reported a 71% reduction in fibroid volume in 8 weeks (Shozu, Murakami et al. 
2003). 
 
Anti-progesterones 
 
Mifipristone 
The use of Mifipristone 5 or 10 mg/day for six months was shown in a study of 40 
symptomatic pre-menopausal women to reduce mean uterine volume by almost 
one half. Mean menstrual blood loss indices decreased significantly with both 
doses from baseline to the end of the study. Some of the side effects associated 
with mifipristone include hot flushes, headache, nausea, decreased libido and 
mood swings. In addition although no atypical hyperplasia was noted, simple 
endometrial hyperplasia occurred in over a quarter of subjects and hepatic 
enzymes were elevated in 8% (Fiscella, Eisinger et al. 2006).  
 
Asoprisnil (selective progestrone receptor modulator) 
Asoprisinil was shown in vitro in uterine leiomyoma cells to down regulate the 
expression of several growth factors (and their receptors) and is thought to have a 
role in the pathogenesis of uterine fibroids (Wang, Ohara et al. 2006). In vitro 
comparisons of its effects on uterine leiomyoma cells and normal myometrial 
cells demonstrated that asoprisnil inhibited proliferation, activated the tumour 
necrosis factor- related apoptosis-inducing ligand mediated signalling pathways, 
and induced apoptosis in leiomyoma cells but not normal myometrial cells, 
suggesting direct targeting of leiomyoma cells (Chen, Ohara et al. 2006) (Sasaki, 
Ohara et al. 2007). Although still investigational, preliminary studies have 
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demonstrated dose–dependent suppression of the duration and intensity of uterine 
bleeding and dose-dependent induction of amenorrhoea. Adverse effects include, 
bloating, flatulence, breast pain and vasomotor symptoms including hot flushes 
and night sweats. (Chwalisz, Larsen et al. 2007). 
 
Cabergoline  
Cabergoline a lysergic acid derivative is a dopamine agonist which is used widely 
in the treatment of prolactinoma and to inhibit lactation. The theoretical basis for 
its use in myoma treatment lies in its inhibitory effect on the secretion of GnRH. 
Only one study, has compared the effects of GnRHa with cabergoline. This study 
found significant fibroid regression with both treatments. The extent of tumour 
regression correlated positively with the number of tumour nodules. Cabergoline 
was well tolerated and had fewer adverse effects compared with GnRHa (Melli, 
Farzadi et al. 2007).   
 
Surgical therapy 
 
Hysterectomy can be used to treat all types of fibroids and is considered the ‘gold-
standard’ treatment for uterine fibroids. By removing the fibroids along with their 
site of origin, this eliminates the existing pathology and the potential for new 
fibroids to develop. Uterine fibroids are the leading indication for hysterectomy 
and hysterectomy has been associated with a patient satisfaction rate of over 90% 
(Farquhar, Harvey et al. 2006). However, hysterectomy may not be an appropriate 
treatment solution for those women still wishing to conceive; therefore, other 
methods have evolved with the goal of sparing the uterus and reducing morbidity. 
Although hysterectomy is the definitive treatment for fibroids, it results in a 
permanent loss of fertility and requires major surgery under general anaesthesia. 
In one recent study, as many as 43% of women who underwent hysterectomy 
expressed regret about their loss of fertility (Farquhar, Harvey et al. 2006). 
Reported complication rates vary from as low as 1.5% to as high as 29.3% 
(Meyers and Steege 1998). Risks include; surgical morbidity/mortality such as 
blood loss, bowel injury, bladder and urethral injury, infection, post-operative 
pain, and death (Farquhar, Harvey et al. 2006). Typical recovery times for 
hysterectomy are approximately 6-8 weeks.  
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Myomectomy, which like hysterectomy has been available for over 150 years, is 
the surgical removal of the fibroids alone and thus preserves fertility. 
Myomectomy can be performed via hysteroscopy, laparoscopy or via laparotomy. 
Laparotomy or abdominal myomectomy, is useful for treating subserosal or 
intramural fibroids (Bernard, Darai et al. 2000), while the hysteroscopic route is 
more appropriate for submucosal fibroids (Wallach and Vlahos 2004). 
Laparoscopic myomectomy is useful for treating easily accessible tumours, such 
as superficial or pedunculated subserosal fibroids (Wallach and Vlahos 2004), a 
proplapsed submucous myoma may also be resected transvaginally.  Comparison 
of outcomes after myomectomy performed by laparotomy or laparoscopy in 
infertile patients revealed that laparoscopic myomectomy was superior in terms of 
febrile morbidity, haemoglobin levels, blood transfusion requirements and post-
operative hospital stay. However, no differences in post-surgery pregnancy rate, 
abortion rate, pre-term delivery rate or caesarean section rate were seen 
(Seracchioli, Rossi et al. 2000). Myomectomy can be difficult in women with 
large, multiple myomas, or in those who have previously undergone multiple 
myomectomies; in these cases, hysterectomy may be preferable (Wallach and 
Vlahos 2004). Surgeons with adequate skill and experience to manage the 
extensive blood loss and uterine reconstruction necessitated by the extensive 
dissection may offer myomectomies in these patients.  
 
Although viewed as less traumatic than hysterectomy, myomectomy is a surgical 
procedure and therefore, surgical morbidity and mortality are disadvantages to 
this approach. There is also the potential for significant blood loss during the 
procedure (Parker 2006). Consequently, various techniques for reducing blood 
loss have been employed; including pre-operative embolisation, misoprostol, 
intramyometrial injection of bupivacaine plus epinephrine, vasopressin, and 
tourniquets (Kongnyuy and Wiysonge 2007). A 20% recurrence rate is reported 
after myomectomy and (Seracchioli, Rossi et al. 2000) and the risk of recurrence 
appears to increase with multiple fibroids (Doridot, Dubuisson et al. 2001; Hanafi 
2005). Additional complications with myomectomy include a high risk of 
adhesion formation and the potential for uterine rupture during pregnancy 
(Frishman and Jurema 2005). Average recovery times vary by the procedure 
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performed; a six to eight week recovery time is associated with abdominal 
myomectomy, whereas patients undergoing a laparoscopic surgery may resume 
normal activities within one to two weeks (Hurst, Matthews et al. 2005) and 
patients receiving a hysteroscopic procedure may recover within seven to ten days 
(Polena, Mergui et al. 2007). 
 
Uterine Artery Embolisation (UAE) 
 
With UAE, the uterine arteries are accessed under fluoroscopic guidance and 
injected with a mass of trisacryl gelatine microspheres or polyvinyl alcohol 
particles for occlusion (see figure 9). 
 
  
 
Chapter 1 fig 9. An illustration of UAE. Embolic material is injected via the 
femoral artery through to the uterine arteries (image courtesy of 
www.northsideradiology.com). 
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Because the uterine arteries are responsible for approximately 94% of the blood 
supply to uterine fibroids, with the remainder received from the ovarian arteries 
via the infundibulopelvic ligament (Kroencke, Scheurig et al. 2006), this 
procedure significantly interrupts the blood supply to the fibroids. It is believed 
that through the induction of transient uterine ischaemia, the small vessels in the 
myometrium become occluded with clots, which are lysed over time as 
fibrinolytic substances from the collateral circulation in the uterus perfuse the 
region. As the fibroids cannot lyse clots, they infarct and undergo ischaemic 
necrosis (Burbank and Hutchins 2000). Consequently this procedure has the 
advantage of treating the uterus globally.  
 
Generally, UAE is most useful in treating intramural fibroids, pedunculated 
fibroids should not be treated with UAE, due to the potential for the stalk to 
infarct and disconnect from the uterus (Marshburn, Matthews et al. 2006). Finally, 
compared to hysterectomy, UAE has been associated with a shorter recovery time 
(< 10 days) and a lower procedural cost (Dembek, Pelletier et al. 2007).  
 
Risks associated with UAE include passage of submucosal myomata, uterine 
necrosis and sepsis and haematoma. UAE has been associated with the potential 
for ovarian failure resulting from unintentional embolisation of the ovarian blood 
supply; in an observational study of 66 pre-menopausal, symptomatic women 
followed for 12-27 weeks after UAE, ovarian failure was found in 43% of patients 
who were at least 45 years of age (Chrisman, Saker et al. 2000). In another study, 
of 108 women trying to become pregnant after UAE, 33 did so (Walker and 
McDowell 2006). The National Institute for health and Clinical Excellence 
(NICE) guidelines on heavy menstrual bleeding, state that ‘women should be 
informed that UAE or myomectomy will potentially allow them to retain their 
fertility’ (Clinical guideline CG44). 
 
Considerable debate remains regarding the optimal management of fibroids, 
however increasingly women are expressing reluctance to undergo open pelvic 
surgery, in particular for a recurrent benign condition. UAE’s effect on fertility is 
at best unclear, especially for women >40 years of age. If the current trend for 
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increasing maternal age at childbirth continues, then an effective non-invasive, 
fertility preserving treatment solution for uterine fibroids is required. 
 
 
1.1.7 Fibroids and fertility 
 
The relationship between leiomyomas and infertility remains a subject of debate. 
The incidence of myomas in infertile women without any obvious cause of 
infertility is estimated to be between 1 and 2.4 % (Buttram and Reiter 1981). 
There are no studies however, that compare pregnancy rates in women with and 
without fibroids and the causal relationship seems to have been assumed from 
case series of women who have conceived after their fibroid was removed 
(Bajekal and Li 2000).  
 
A variety of theories have attempted to provide an explanation of how fibroids 
may cause infertility. One theory explains that fibroid sufferers may have 
anovulatory cycles resulting from the hyper-oestrogenic environment (Buttram 
and Reiter 1981), another explains that changes caused by fibroids such as 
elongation and distortion of the endometrial glands, cystic glandular hyperplasia 
and endometrial venule ectasia may be responsible for implantation failure 
(Deligdish and Loewenthal 1970). Another theory may be that sperm migration or 
ovum transport can be affected by the dysfunctional uterine contractility caused 
by fibroids (Deligdish and Loewenthal 1970). 
What is generally agreed on however is that the anatomical location of the fibroid 
is important in its effect on fertility.  Sub-mucosal fibroids are seen as the most 
problematic due to the distortion caused to the endometrial cavity and the possible 
disruption to endometrial blood supply. Local inflammation caused by mucus 
ulceration can change the biochemistry of the intrauterine fluid.  The role of 
intramural fibroids is more controversial. Subserosal and pedunculated fibroids, 
with greater than 50% of their mass outside the myometrial border are seen as 
unlikely to cause adverse outcomes (Richards, Richards et al. 1998). 
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Fibroids and outcomes of Assisted Reproductive Technology (ART) 
 
The effect of uterine fibroids on fertility in association with the use of ART has 
been the subject of many published articles. Studies of women undergoing in-vitro 
fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI) have 
demonstrated that submucosal and intramural fibroids in the presence of distortion 
of the endometrial cavity are associated with reduced implantation and pregnancy 
rates compared with women with similarly located fibroids in the absence of 
endometrial cavity distortion.  This has been shown with both small (<5 cm 
diameter) (Farhi, Ashkenazi et al. 1995; Stovall, Parrish et al. 1998) and large 
(>4cm) intramural fibroids (Oliveira, Abdelmassih et al. 2004). Some studies 
however have also reported impaired IVF and ICSI outcomes in the presence of 
sub-serosal fibroids (Oliveira, Abdelmassih et al. 2004) (Stovall, Parrish et al. 
1998). In contrast, other authors have shown that ART outcomes are not affected 
by the presence of subserosal myomas. In this same study the authors reported 
significantly lower pregnancy and implantation rates in the presence of both 
intramural and submucosal fibroids, even when associated with an undistorted 
endometrial cavity (Eldar-Geva, Meagher et al. 1998) The relationship between 
uterine fibroids and ART has been investigated repeatedly, and whilst study 
outcomes are often conflicting, overall the evidence supports the concept that 
submucosal and intramural fibroids which distort the endometrial cavity have a 
negative impact on outcomes of ART. However, the effects on fertility of both 
subserosal and intramural fibroids in the presence of a normal endometrial cavity 
remain unclear.  
 
Fertility following myomectomy 
 
Whilst hysterectomy remains the gold-standard treatment for fibroids, in terms of 
eliminating fibroid-associated symptoms immediately and guaranteeing no 
recurrence of symptoms, it is an unacceptable treatment option for women who 
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wish to conserve their fertility. Myomectomy, which involves removal of the 
fibroid with conservation of normal myometrial tissue and hence fertility, remains 
the alternative surgical treatment option for women who wish to conceive in the 
future, although the actual effects of the procedure on fertility remain uncertain. 
Studies on clinical outcomes following myomectomy have yielded inconsistent 
data, and tend to be of poor design, many being retrospective and uncontrolled. In 
a retrospective study, Surrey et al did not find a significant difference in outcomes 
in terms of implantation, ongoing pregnancy or early pregnancy loss rates when 
comparing both pre-cycle abdominal myomectomy and hysteroscopic resection of 
small submucosal fibroids with control (Surrey, Minjarez et al. 2005). In contrast, 
a number of retrospective observational studies have highlighted that fertility 
outcomes do improve after myomectomy (Dubuisson, Fauconnier et al. 2000) 
(Rossetti, Sizzi et al. 2001). However, there are no published randomised 
controlled studies with sufficient power to support the theory that myomectomy 
improves fertility outcome. Similarly, there is no evidence at present to suggest 
that there is any difference in clinical pregnancy and live-birth rates between the 
various techniques available to remove fibroids (Griffiths, D'Angelo et al. 2006). 
 
Fibroids and miscarriage 
 
Fibroids have the potential to cause a number of problems in pregnancy, including 
miscarriage and pregnancy wastage. A number of studies have shown that 
spontaneous miscarriage rates in the first and second trimesters of pregnancy are 
higher in women with fibroids. Some believe that the rates of miscarriage are 
likely to be higher if implantation occurs over a sub-mucosal myoma. It has been 
shown that fibroids in close proximity to the placenta are more likely to be 
associated with bleeding in early pregnancy and spontaneous miscarriage 
(Muram, Gillieson et al. 1980) (Rosati, Bellati et al. 1989). Benson et al 
demonstrated almost double the rate of spontaneous pregnancy loss in women 
with fibroids compared with age-matched women with normal uteri (Benson, 
Chow et al. 2001). In addition, the loss rate observed was found to be higher in 
women with multiple fibroids compared with women with a single myoma, whilst 
no association between loss rate and fibroid size or location was noted. 
Miscarriage rates in women with fibroids vary widely in the literature, with loss 
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rates of 40% in the first trimester and 17% in the second trimester being reported 
in the presence of intramural and submucosal fibroids (Li, Mortimer et al. 1999).  
 
 
Summary 
 
In counselling patients with fibroids pre-conceptually, it is important to recognize 
that most patients with asymptomatic fibroids can conceive spontaneously. In 
patients presenting with infertility, sub-mucosal fibroids have been associated 
with markedly lower ongoing pregnancy rates in small studies, but no 
randomized, controlled trials evaluating the benefit of hysteroscopic myomectomy 
have been reported. Women with intramural fibroids should be counselled that 
there is conflicting evidence on the effect that these fibroids have on infertility, 
with the cumulative effect of such lesions unlikely to be large. Subserosal fibroids 
appear to have no effect on fecundity. 
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CHAPTER 1.2:  PHYSICS OF MAGNETIC RESONANCE 
GUIDED FOCUSED ULTRASOUND SURGERY 
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1.2.1 Background 
 
The concept of ‘the perfect’ tumour surgery is to excise or remove the neoplastic 
tissue without damaging adjacent normal structures. This concept requires a non-
invasive non-incisional surgical approach, which limits the tissue destruction to 
the targeted tumour. Non-invasive surgery would lead to even shorter recovery 
time and result in even less complications than currently available minimally 
invasive techniques. Implementing such non-invasive surgical procedures will 
transform current medical specialities, change existing clinical practices and could 
therefore be an important tool in reducing the cost of patient care. In the surgical 
speciality, emphasis on manual skills and practical training will be replaced by a 
mostly technical knowledge base. Patients will return home and to work much 
faster without any significant reduction in quality of life caused by the procedure. 
 
Magnetic Resonance guided Focused Ultrasound (MRgFUS) is such a technology. 
Unlike invasive surgery, it requires no incision, and the acoustic energy penetrates 
through intact skin and through the tissues surrounding the tumour, without 
causing any significant bio-effects. Energy deposition takes place mainly at the 
focal spot where heat-induced thermal coagulation of the targeted tissue is 
accomplished. As in ionising radiation- based therapy, the localisation of the 
target volume requires image guidance. Using intra-procedural MRI, this 
technique provides the best possible tumour margin definition and with real-time 
MRI thermometry, the closed loop feedback control of energy deposition is also 
accomplished. This real-time targeting and control makes MRgFUS superior to 
radiation surgery. In addition because of the lack of any tissue toxicity, Focused 
Ultrasound Surgery (FUS), unlike radio-surgery, can be repeated multiple times if 
necessary. 
 
The idea of using focused acoustic energy for thermal coagulation deep within the 
tissue as a non-invasive surgical method is not new. It was first proposed over 60 
years ago for the destruction of central nervous system tissue (Lynn, Zwemer et 
al. 1942). In the 1950s, a complex sonication system that used x-rays to determine 
the target location with respect to skull bones was developed by William and 
Francis Fry at the University of Illinois (Fry, Barnard et al. 1955; Fry, Barnard et 
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al. 1955). The system was clinically tested for the treatment of Parkinson’s 
disease with success, but was not used outside the research setting (Fry and Fry 
1960). The primary difficulty with the treatment was the localisation of target 
tissues and the complexity of the procedure. The use of ultrasound for image 
guidance soon superseded the use of x-rays (Fry 1970), and remains in current 
practice.  
 
Currently two trans-rectal ultrasound surgery devices for prostate cancer are in 
clinical use in Europe and several other countries. Furthermore, external 
ultrasound-guided devices are in clinical use in China, where tens of thousands of 
patients have been treated so far. Although targeting using diagnostic ultrasound 
works well in some cases, treatment is still relying on open-loop, uncontrolled 
energy delivery. This means that the power settings for the exposures are based on 
experimental and theoretical models as well as clinical experience with no live 
monitoring of the target location or temperature levels achieved.  
 
This makes the treatment sensitive to patient-to-patient variations. Just the 
propagation of the wave through the overlying tissue layers can significantly 
distort the power deposition pattern at the focus (Liu, McDannold et al. 2005). To 
eliminate these variations, the energy delivery and its biological effects should be 
monitored online, and exposure variations should be adjusted to give comparable 
thermal exposure to all patients whilst avoiding over-exposure of tissues outside 
of the target volume. 
 
The advent of MR and its temperature sensitivity allowed for real-time thermal 
monitoring (Jolesz, Bleier et al. 1988) and thus the development of ultrasound 
surgery systems combined with MRI. This allowed not only the monitoring of 
online temperature information received, but perhaps more importantly, more 
accurate definition of the targeted tumour volume than surgical inspection with 
the eye or other imaging modalities such as ultrasound or computed tomography. 
 
Currently there is only one commercial device available on the market, the 
ExAblate 2000 manufactured by Insightec Ltd, Haifa. The device has been 
approved in the United States by the Food and Drug Administration for the 
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treatment of uterine fibroids. It has been recognised by the National Institute of 
Clinical Excellence, and has been awarded the conformitee europeenne (CE mark) 
for fertility. 
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1.2.2 Fundamental principles of therapeutic Ultrasound 
 
Ultrasound is a pressure wave with a frequency above the audible range of a 
human ear (18-20KHz); it is generated by a mechanical motion that induces the 
molecules in a medium to oscillate around their rest positions. Due to the bonding 
between the molecules, the disturbance is transmitted to neighbouring molecules. 
The motion causes compressions and rarefactions of the medium and thus a 
pressure wave travels with the mechanical disturbance (figs 10 and 11). 
 
 
 
Chapter 1 Figure 10: A mechanical ultrasound wave progresses through 
tissues (top), causing alternating cycles of increased and reduced 
pressure (compression and rarefaction respectively- bottom). Image 
courtesy of www.olipiados.it/components.com. 
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Chapter 1 Figure 11: The particle movement responsible for the 
propagation of longitudinal and shear waves. Image courtesy of 
www.me.berkeley.edu/-adarsh/masters.pdf 
 
As a result, an ultrasound wave requires a medium for propagation. In most cases, 
the molecules vibrate along the direction of the propagation (longitudinal wave), 
but in some instances, the molecular motion is across the direction of the wave 
propagation (shear wave). Shear waves propagate in solids such as bone but are 
quickly attenuated in soft tissues. Therefore, most current medical ultrasound 
methods utilise longitudinal waves (Wells 1977). 
 
1.2.3 Ultrasound transducers 
 
Ultrasound is generated by applying radio-frequency voltage across a material that 
is piezoelectric, that is it expands and contracts in proportion to the applied 
voltage. This phenomenon is the inverse of the piezoelectric effect, which was 
discovered by Jacques and Pierre Curie in natural quartz crystals in 1880. Since 
then, many piezoelectric materials have been discovered and developed. From 
these materials, a group of artificial piezoelectric materials known as polarised 
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polycrystalline ferroelectrics are used for medical ultrasound applications. The 
piezoelectric property is lost above a material–specific temperature- the Curie 
point. Also, piezoelectric material rods or grains can be placed into a polymer 
matrix to have more control over the acoustic and electrical properties of the 
material. These so called piezo - composite materials are used especially in phased 
array transducers. 
 
For many applications of ultrasound therapy, transducers capable of producing 
high-power, single-frequency, continuous waves are needed. In figure 12, a 
simplified version of a high-powered transducer is shown. 
 
Chapter 1 Figure 12: Diagram of an ultrasound therapy transducer.    
                                   
The ultrasound wave is generated by a piezoelectric plate of uniform thickness 
that has electrodes on its front and back surfaces. The electrodes are connected to 
the driving radio-frequency line. Maximum power from a transducer can be 
delivered when it is operated close to its resonant frequency, which is achieved 
when the thickness of the plate is equal to the wavelength/2. However, a range of 
frequencies can be used with piezo composite materials. The frequency, which 
corresponds to the half-wavelength thickness, is called the fundamental resonant 
frequency of the transducer and it gives the maximum displacement amplitude at 
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the transducer faces. The transducer can be driven at a frequency which is three, 
five or so on times its fundamental frequency. The conversion efficiency is, 
however, reduced when compared with the fundamental frequency operation. At a 
frequency of 1 MHz, the half-wavelength thickness is approximately 2 mm in 
PZT-4, thus high-frequency transducers are thin and more difficult to 
manufacture. 
 
In order to maximize energy output, all of the acoustic energy should be radiated 
through the face of the transducer. This can be achieved by selecting a backing 
material so that the acoustic impedance of the transducer is much larger than the 
acoustic impedance of the backing. In practice, air-backing gives almost complete 
energy transmission through the front of the transducer. 
 
Ultrasound transducers can be manufactured in practically any desired shape and 
size. Spherically curved focused transducers of various sizes up to 30 cm diameter 
hemispherical transducer arrays have been manufactured (Ebbini and Cain 1991; 
Clement, Sun et al. 2000; Hynynen, Clement et al. 2004). Both non-focused and 
focused, single and multi-element transducers and arrays have been manufactured 
for endo-cavity use (Diederich and Hynynen 1989). Interstitial applicators 
inserted directly into the tissue via catheter have been constructed down to the 
size of 1mm in diameter (Hynynen 1992). Catheter based applicators, inserted via 
the vascular route into the heart, have been developed for ablating cardiac tissue 
(He, Zimmer et al. 1994). Special care in the selection of transducer materials has 
to be taken when applicators for use in magnetic resonance imaging (MRI) - 
guided interventions are developed.  
 
1.2.4 Focused ultrasonic fields 
 
The ultrasound field generated by a transducer depends on the size, shape and, 
vibration frequency of the source. If the diameter of an ultrasound source is much 
larger than the wavelength in the medium, then the ultrasonic wave can be 
focused by lenses or reflectors, or by making the transducer self-focusing. 
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Focusing can be achieved by using arrays of small transducers that are driven with 
signals having suitable phase delays to obtain a common focal point (electrical 
focusing). The wavelength imposes a limitation on the size of the focal region and 
the sharpness of the focus is determined by the ratio of the aperture of the radiator 
to the wavelength, and the distance of the focus from the transducer (see figure 
13) 
                                                      
 
 
Chapter 1 Figure 13:  Ultrasound beams may be focused
 
 by curving the 
piezoelectric plate or by interposing a lens or reflector between a flat plate 
and the target. A phased array of transducers is focused electronically. 
Image courtesy of citeseerx.ist.psu.edu. 
 
The theory of spherically curved transducers vibrating with uniform normal 
surface velocity was developed by O’Neil in 1949. It is possible to focus energy 
in the near field of an equivalent diameter planar transducer, due to the finite size 
of the wavelength. The ultrasound field between the acoustical focus and the 
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transducer resembles the near field of a planar transducer. Beyond the focus, the 
field follows the geometrical divergence angle of the transducer. The shape of the 
focus is a long narrow ellipsoid with dimensions dependent on the transducer 
diameter, radius of curvature, and frequency. The geometrical focusing of a 
transducer is often described by an F-number, which is the ratio between the 
radius of curvature and the diameter of the transducer (F-number = R/d). By 
increasing the radius of curvature (R), the maximum intensity can be pushed 
deeper into the tissue but at the cost of the focal region becoming longer and the 
peak intensity lower. This is due to the reduced focusing effect of the transducer 
and the attenuation within the tissue. It is possible to induce an intensity 
maximum at any practical depth in a human body with a suitable choice of 
transducer parameters, as long as the beam entry is not restricted by gas or bone 
(Hynynen, Watmough et al. 1981). 
 
 
1.2.5 Electrical Focusing 
 
Ultrasonic beams can be focused by using one or two dimensional arrays of 
transducers, with each element driven by radio-frequency signals of a specified 
phase and amplitude, so that the waves emitted by all of the elements are in phase 
at the desired focal point. The element size will determine the volume within 
which the focus can be moved because the focus has to be within the volume 
where all of the beams generated by the elements are overlapping. Focusing to a 
location outside this volume will result in secondary focal spots. An ultrasound 
beam can be focused anywhere in front of the array when the element centre-to-
centre spacing is wavelength/2 or smaller see figure 13 above. 
 
So far, all of the phased array systems developed for ultrasound treatments have 
had a limited focal range because the large size of the arrays needed results in 
thousands of elements. However, it has been demonstrated that adequate power 
outputs can be achieved with wavelength/2 test arrays (70) and thus there is no 
technology barrier to constructing such arrays. 
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Although electric focusing and beam steering has been used extensively in 
diagnostic ultrasound (Pernot, Aubry et al. 2003), its adoption in therapy systems 
has been much slower. The first attempt to utilise electrical focusing in ultrasound 
therapy was by Do-Huu and Hartemann (Do-Huu et al 1981). They constructed a 
concentric ring transducer that allowed the focus to be moved along the axis but 
not in any other direction. A full range of axial focal spot movement can be 
achieved with ring centre spacing of one wavelength (Ebbini and Cain 1991). 
Large spacing can be used if the array is spherically curved and the focal range is 
limited (Diederich and Hynynen 1991). A similar approach can be used for 
achieving a limited range, three-dimensional motion with phased arrays with large 
element sizes (Ebbini and Cain 1991). 
 
There has been a lot of progress in using phased arrays for ultrasound surgery and 
especially for MRI- guided ultrasound surgery (Daum and Hynynen 1999). 
Today, phased arrays are the method of choice for clinical devices, with the 
concentric ring design providing control over the depth of focus with added 
sectors to provide limited beam steering to make the focus larger (Fjield, Fan et al. 
1996). Phased arrays have also made it possible to compensate for wave distortion 
induced by overlying tissues such as skull (Clement, Sun et al. 2000). Similarly, 
phased arrays offer significant advantages for applicators that deliver the 
ultrasound energy via body cavities (Hutchinson, Dahleh et al. 1998). 
 
1.2.6 Biological effects of ultrasound 
 
Ultrasound interacts with tissue through the particle motion and pressure variation 
associated with wave propagation. First, all ultrasound waves are continuously 
losing energy through absorption resulting in an increase in temperature within 
the tissue. If the temperature elevation is large enough and is maintained for an 
adequate period, the exposure causes tissue damage. This thermal effect that can 
be used for tissue coagulation or ablation is similar to that obtained using other 
heating methods with equal thermal exposure. Secondly, at high-pressure 
amplitudes, the pressure wave can cause formation of small gas bubbles that 
concentrate acoustic energy. Similar focusing of energy can be induced by the 
oscillation of small bubbles already present. This type of interaction between a 
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sound wave and a gas body is called cavitation and it can cause a multitude of bio-
effects from cell membrane permeability changes to complete destruction of 
tissue. Finally, the mechanical stress and strain associated with wave propagation 
may sometimes cause direct changes in a biological system. The mechanical 
interactions between ultrasound and tissue include radiation force and pressure, 
radiation torque, and streaming (shearing stress).  
 
 
1.2.7 Thermal effects 
 
The thermal effects produced by ultrasound have been utilised in hyperthermia as 
a cancer therapy as well as in many ultrasound surgery applications. In order to 
induce thermal tissue damage, the exposure at a given temperature has to exceed a 
threshold time below which the tissue recovers. The thermal damage threshold 
depends amongst other things on tissue type and physiological factors (pH and 
O2). A given intensity or power of the ultrasonic field does not necessarily induce 
a known temperature elevation. The temperature elevation in a tissue depends on 
the absorption and attenuation coefficients of the tissue, the size and shape of the 
ultrasound field (thermal conduction effects), and also strongly on the local blood 
perfusion rate.  
 
At short exposures, in the order of seconds, the blood perfusion effects are small 
and the heat transference is dominated by thermal conduction (Billard, Hynynen 
et al. 1990) (Kolios, Sherar et al. 1996). At longer exposures, perfusion dominates 
the heat transfer and thus has a major impact on the actual temperature elevation 
achieved. All of these tissue parameters (except thermal conduction) vary from 
tissue to tissue and location to location. Therefore the temperature elevation 
during an ultrasound exposure has to be measured to ensure that adequate thermal 
exposure has been achieved. (Sapareto and Dewey 1984; Dewhirst, Viglianti et al. 
2003). 
 
Although the actual temperature threshold varies from tissue to tissue, the 
threshold is linearly proportional to the log of exposure duration such that a 10 C 
temperature increase reduces the required exposure duration to half. This 
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relationship is characterised by a thermal dose equation that describes the thermal 
exposure as the time in minutes at 430 
 
C that achieves an equivalent bio-effect 
(Dewhirst, Viglianti et al. 2003). To summarise from thermal exposure literature, 
a thermal dose of 240 minutes at 43ºC is sufficient to cause necrosis in all tissues 
(Sapareto and Dewey 1984; Dewhirst, Viglianti et al. 2003). Similarly, all tissues 
can survive an exposure of a few minutes at 43ºC. there are however many 
potentially useful thermal effects at exposures that do not cause tissue necrosis, 
for example, sensitization of tumours to radiation or chemotherapy (Dewhirst, 
Viglianti et al. 2003) and the increase of tissue perfusion such that higher quantity 
of drugs could be delivered in the tissue. Thermal exposures can enhance the 
blood vessel permeability, release therapeutic agents from liposomal carriers 
(Magin and Niesman 1984) (Needham and Dewhirst 2001), and activate drugs or 
gene therapy (Moonen 2007). MRI guided focused ultrasound can offer highly 
controllable thermal exposures and thus may provide a method to explore the 
clinical use of these non-lethal thermal exposures. 
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1.2.8 Fundamental principles of Magnetic Resonance Temperature 
Imaging 
 
Clinical Magnetic Resonance Imaging (MRI) uses the magnetic properties of 
hydrogen and its interaction with both a large external magnetic field and radio-
waves to produce highly detailed images of the human body. 
 
In its early days, MRI was known as NMR. This stands for Nuclear Magnetic 
Resonance. Although the name has changed (primarily due to the negative 
connotation of the word “nuclear”), the basic principles are the same.  
 
MRI produces images by using a magnetic field to induce changes in proton spin 
within tissues. Normally, the magnetic axes of multiple protons within tissues are 
randomly aligned. When surrounded by a strong magnetic field, as in an MRI 
machine, the magnetic axes align along the field. Application of a radiofrequency 
pulse causes the axes of all protons to momentarily align against the field in a 
high-energy state; some protons then relax back to their baseline state within the 
magnetic field. The magnitude and rate of energy release that occurs with return 
to baseline alignment (T1 relaxation) and with the wobbling (precession) of 
protons during the process (T2 relaxation) are recorded as spatially localized 
signal intensities by a coil (antenna). These intensities are used to produce images. 
The relative signal intensity (brightness) of tissues on an MR image is determined 
by multiple factors, including the radiofrequency pulse and gradient waveforms 
used to obtain the image, intrinsic T1 and T2 tissue characteristics, and tissue 
proton density. 
Pulse sequences are computer programs that control the radiofrequency pulse and 
gradient waveforms, which determine how an image is weighted and how various 
tissues appear. Images can be T1-weighted, T2-weighted, or proton density–
weighted. For example, fat appears bright (high signal intensity) on T1-weighted 
images and relatively dark (low signal intensity) on T2-weighted images; water 
and fluids appear as intermediate signal intensity on T1-weighted images and 
bright on T2-weighted images. T1-weighted images optimally show normal soft-
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tissue anatomy (fat planes are well seen as high signal intensity) and fat (e.g. to 
confirm a fat-containing mass). T2-weighted images optimally show fluid and 
pathology (e.g. tumours, inflammation and trauma). In practice, T1- and T2-
weighted images provide complementary information, so both are important for 
characterizing pathology. 
Contrast may be used to highlight vascular structures (magnetic resonance 
angiography) and to help characterize inflammation and tumours. The most 
commonly used agents are gadolinium derivatives, which have magnetic 
properties that affect proton relaxation times. Gadolinium agents can cause 
nausea, pain, sensation of cold at the injection site, taste distortion, vasodilatation, 
and reduced threshold for seizures. Serious contrast reactions are rare and much 
less common than those with iodinated contrast agents (Jacobson, JA 2008). 
 
1.2.9 Temperature sensitivity of magnetic resonance imaging 
 
Since both the chemical environment and relaxation properties of the nuclei that 
are the source of the signal in Magnetic Resonance (MR) are sensitive to 
Brownian motion and the associated molecular tumbling rates, MR imaging 
(MRI) techniques are intrinsically sensitive to temperature. Of the many MR 
parameters that can provide temperature sensitive contrast, the temperature 
dependence and sensitivity of several parameters in particular, have proven useful 
for monitoring temperature changes in soft tissue during delivery of hyperthermia 
or thermal therapies: the apparent diffusion of constant of water (D), the spin-
lattice relaxation time (T1
 
), and the water proton resonance frequency (PRF). The 
temperature sensitivities associated with each of these parameters are large 
enough to allow temperature-dependent changes to be observed quantitatively 
using either direct or indirect measurements using standard MRI devices over a 
range of temperature relevant for thermal therapy. The development of these 
techniques to non-invasively measure temperature changes in tissue has brought 
renewed interest in using these techniques to enhance the guidance of thermal 
therapy treatments. 
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Of the available radiological imaging modalities capable of providing real-time 
temperature feedback, MRI has the desirable properties of excellent soft-tissue 
contrast and the ability to provide fast, quantitative temperature imaging in a 
variety of tissue (Cline, Schenck et al. 1992; Hynynen, Darkazanli et al. 1993).   
 
By far the most exploited and widely validated quantitative MR temperature 
imaging techniques are based on the temperature sensitivity of the water proton 
chemical shift or phase shift (McDannold 2005) and the T1 weighted (T1W) 
signal. Diffusion weighted imaging is based on thermal Brownian motion but is 
impractical in vivo because of long scan time and subsequent motion artefact (Le 
Bihan, Delannoy et al. 1989).  
 
Phase shift exploits the phase of the MR signal rather than the magnitude. As 
temperature rises, phase changes, thus producing an excellent thermal map (Harth, 
Kahn et al. 1997). However phase shift is also highly sensitive to motion and to 
magnetic field inhomogenities causing artefact, this is a particular problem in the 
abdomen due to significant inherent physiological motion (Harth, Kahn et al. 
1997) (Botnar, Steiner et al. 2001). T1W dependent temperature mapping is based 
on a linear inverse relationship between T1 signal and temperature. As 
temperature rises, T1 signal is lost, with signal becoming increasingly blacker on 
T1 images (Matsumoto, Oshio et al. 1992). A software tool is used to produce 
colourised thermal maps of heated areas during heat application for real-time 
temperature quantification Sun Micro  Systems Sparc 20 (Jiang and Zhang 2005) 
This is particularly useful for showing the very early thermal changes before 
irreversible necrosis has occurred. The grey-scale loss in T1 signal is converted to 
a colour spectrum, which ranges from blue (coolest area), through turquoise, 
green and yellow to red (the hottest area) (de Jode, Lamb et al. 1999). The images 
are updated every 1.5s at approximately 55°C, irreversible tissue necrosis occurs 
corresponding to a persistent green colour on the colour scale.  
 
The advantage of real-time imaging and thermal mapping is that it allows the 
operator greater control and accuracy over the treatment, the duration of heat and 
power applied can be varied as required to produce reliable, consistent results 
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each time, with maximum safety assured. Without real time imaging the extent of 
tissue necrosis can only be approximated (de Jode, Lamb et al. 1999).  
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CHAPTER 1.3: FROM 1st GENERATION TO 3rd
 
 
GENERATION THERMOABLATION FOR UTERINE 
FIBROIDS. 
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1.3.1 Background 
 
The principles of thermal ablation are that the application of heat leads to a 
localised tissue destruction. Since the resulting cell necrosis is a coagulative rather 
than an ischaemic process, the painful infarction syndrome which is recognised 
after UAE is avoided (Freed and Spies 2010). 
 
First generation thermal ablation was delivered via the laparoscopic approach 
(Goldfarb 1992). Although this procedure achieved good symptom relief, 
concerns were raised regarding the high rate of dense pelvic adhesions following 
the introduction of the live laser fibres into the fibroid at laparoscopy (Donnez, 
Squifflet et al. 2000).  Damage to the uterine serosa was frequently noted due to 
lack of thermal monitoring. The operator had to rely on a change in the external 
appearance of the fibroid as the only means of assessment that sufficient heat had 
been applied. 
Reports of uterine rupture prior to the onset of labour did little to improve 
confidence in this technique and indeed it was later suggested that laparoscopic 
myolysis be reserved for women who had completed their families (Arcangeli and 
Pasquarette 1997) (Vilos, Daly et al. 1998). 
 
Second generation thermal ablation techniques relied on the superiority of 
magnetic resonance as an imaging modality and its unique ability to create 
thermal mapping using phase shift imaging. This gives the operator real time 
colour map feedback on the temperature levels achieved, together with 
reassurance that heating is occurring only in the target tissue, thus ensuring both 
the safety and efficacy of the treatment (Law, Gedroyc et al. 1999). 
 
The technique of MR guided laser ablation was made possible by the design of an 
open magnet (see figure 14) which allows the operator direct access to the patient. 
The open scanner is composed of 2 magnet rings ‘the double doughnut’ through 
the centre of which is placed the patient on the MR table. The scanner allows 
access to the patient in the vertical plane between the two magnet rings, the 
operator can stand beside the patient and insert four double bore needles 
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percutaneously through the abdominal wall and into the uterine fibroids (See 
figure 15). The protective inner sheath is then pulled back and the live laser fibres 
are thread through and inserted into the fibroids. The procedure is carried out 
under real time MRI guidance ensuring that the bladder and bowel can be 
avoided. The thermal ablation begins distant from the serosal surface and 
therefore serosal damage is limited to the puncture wounds.  
 
 
 
 
Chapter 1 Figure 14:  Photograph of the open scanner, showing the ‘double 
doughnut’ rings, which allow operator access to the patient. 
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Chapter 1 Figure 15:  Photograph of the operator inserting percutaneous laser 
fibres. 
 
Hindley, et al 2002, described a total of 66 patients with symptomatic uterine 
fibroids wishing to avoid surgery, who were treated were MR guided laser 
ablation (Hindley, Law et al. 2002). MR thermal mapping ensured that maximal 
doses of energy were applied. Fibroid volume was measured at 3 and 12 months 
post laser ablation, menstrual blood loss was quantified before and after treatment 
and a menorrhagia outcomes questionnaire (MOQ) was used to assess patient 
symptoms and satisfaction. There was a reduction in mean fibroid volume of 31% 
at 3 months and 41% at 1 year. Quality of life symptom- severity scores were 
similar to those seen in women undergoing hysterectomy. In summary, 80% of 
patients said they would recommend the procedure to a friend. In direct contrast to 
laparoscopic laser ablation, there were no cases of pelvic adhesions. 
Approximately 150 women have now been treated with MR guided percutaneous 
laser ablation with consistently good outcomes. 
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1.3.2 Magnetic Resonance guided Focused Ultrasound Surgery. 
 
As mentioned previously, this method of thermoablation, is a completely non-
invasive method of achieving tissue destruction by acoustic energy that converts 
to heat during absorbtion. While other methods of thermoablation are only 
minimally invasive because of the use of percutaneous needles and needle-like 
probes, MRgFUS is completely non-invasive with no percutaneous probes 
required. The US waves penetrate soft tissue and can be focused to small focal 
volumes with dimensions of a few milimetres. The acoustic energy absorption at 
the focal spot leads to tissue temperature elevations with such sharp thermal 
gradients that the boundaries of the treated volume are sharply demarcated 
without damage to the over-lying or surrounding adjacent tissues. No other probe-
delivered heating methods can achieve similar, well-controlled, deep thermal 
ablation. 
 
MRgFUS effectively combines two technologies (MRI and US) into a non-
invasive image-guided therapy delivery system that fulfills the requirements of the 
‘ideal surgery’ in that it is a method which ensures only the targeted tumour tissue 
is destroyed without associated injury of the adjacent normal tissue, by using a 
precisely focused, high-power acoustic beam (see figure 16). Before the sound 
waves are concentrated at the focus point, they propagate through the tissue 
without damaging it. At the focus, the intensified acoustic energy beam raises the 
tissue temperature to arange where tissue is coagulated by protein denaturation 
and capillary bed destruction.        
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Chapter 1 Figure 16:  Illustration showing high frequency ultrasound beam 
generated by the transducer, passing through the abdominal wall and 
being targeted at a fibroid. Only tissue at the focus is damaged. (image 
courtesy of Inisghtec). 
    
 
MRI, with its excellent sensitivity for imaging soft-tissue tumours, is preferable 
over other imaging modalities for localizing 3D tumour margins and targeting 
tumour volumes. In addition, because of the excellent temperature sensitivity of 
MR, the focal point can be visualised and localised well before any irreversible 
tissue damage is induced at about 20°C above normal body temperature. 
Moreover, MRI’s ability to capture the temperature change enables the physician 
to delineate temperature maps and tumour volume and apply this quantitative 
information in real time (Jolesz and Hynynen 2002) (Jolesz, Hynynen et al. 2005). 
 
Successful design, testing, and development of a clinical MRgFUS system was a 
significant engineering challenge. Following the early implementation of the 
technique (Hynynen, Freund et al. 1996) and after the development of a prototype 
workstation at the Brigham and Women’s Hospital by McDannold et al, Insightec 
(Haifa, Israel) developed the first commercial MRgFUS therapy delivery system 
known as the ExAblate®2000. It is this system which has been used throughout 
the work of this thesis. 
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1.3.3 System Components 
 
The Exablate 2000 system consists of the following integrated components: 
x Operating console 
x Patient table 
x Equipment cabinet 
x Cooling system 
 
Operating console. 
 
The Exablate 2000 console allows the operator to control and monitor both the 
system and the treatment. It positioned alongside the GE SIGNA workstation in 
the control room. (see figure 17) 
 
 
                                
Chapter 1 Figure 17:  the operating console of the ExAblate 2000 MRgFUS 
system. 
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Patient table 
 
Treatments are conducted with the patient lying on the patient table inside the MR 
scanner (see figure 18). 
The patient table contains the focused ultrasound transducer along with the 
mechanical positioning unit that moves the transducer (see below). Prior to 
treatment, the patient table is docked to the MR scanner. A quick-coupler cable 
connects the patient table to the equipment cabinet. 
 
 
 
 
Chapter 1 Figure 18:  Showing the modified patient table containing the 
unltrasound transducer. The transducer is able to move in 3 planes. 
(Images courtesy of InSightec). 
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Equipment cabinet 
 
The equipment cabinet contains the electrical components of the Exablate 2000 
system and the main power switch (see figure 19).                  
                       
Chapter 1 Figure 19:  The equipment cabinet of the ExAblate 2000 system. 
(Image courtesy of Insightec). 
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Cooling system 
 
The cooling system incorporates a semi-closed water circulation loop, designed to 
keep the water in the transducer bath at an optimally low temperature during 
operation.  
 
The circulating water is never in direct contact with the human body (see 
figure20). 
 
   
                                
         
Chapter 1 Figure 20:  The cooling unit of the ExAblate 2000 system. (Image 
courtesy of Insightec).               
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1.3.4 The Treatment process 
 
All MRgFUS procedures, except those in chapter 3, performed for the purpose of 
this thesis were performed or supervised by S. Zaher.  
 
Treatment is conducted while the patient lies on a patient table inside the 
Magnetic Resonance scanner.  The patient is conscious, able to communicate with 
the physician during the treatment, and is provided with sedation medication prior 
to the first sonication.  The entire procedure is planned and carried out from the 
operator console.   
There are four major steps in the ExAblate treatment: 
 
Target localization 
MR images are taken in three orientations to locate the target tissue and 
surrounding organs (see figure 21). These images are used to position the patient 
and determine the optimal path to the tumour for the focused ultrasound beam. 
 
 
 Coronal    Axial    Sagittal 
 
Chapter 1 Figure 21:  Target tumour is localised in three orientations.  
 
 
 
Coronal Axial  
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Treatment planning and editing 
 
The physician uses the MR images to identify the target anatomy and evaluates 
the structures surrounding the fibroid to decide on a treatment region. Bowel, 
pubic bone and far field bone are marked as low energy density regions (LEDR). 
This prevents the beam path from coming close to any of these regions and 
thereby avoiding potential complications such as bowel perforation or 
neuropraxia. 
 
 Contours of the treatment area are drawn on the MR images and verified in three 
orientations. The Ex-Ablate system calculates the volume of the tissue to be 
treated and the number of treatment spots required. The beam path is visualized to 
verify that nothing interferes in any plane. 
 
 
 
Treatment 
Treatment consists of multiple sonications to ensure tumour ablation. During each 
sonication, phase sensitive MR images are acquired, and real-time quantitative 
temperature maps are produced to confirm tissue heating. These temperature maps 
provide feedback to the physician who can then adjust treatment parameters to 
optimize thermal ablation. After each sonication, the transducer and MR scan 
plane are automatically directed to the succeeding point, and the process is 
repeated until the entire target volume has been treated. 
 
 
 
 
 
73 
      
 
Chapter 1 Figure 22:  Sample screen showing the treatment target tissue being identified and markers placed around the 
borders (red crosses) these markers help to identify if movement occurs.
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Transducer Tilt
Indicator
 
  
Chapter 1 Figure 23: Sample screen showing skin line drawn on axial images, temperature levels can be measured at 
the skin to ensure safe levels. Bowel is marked as a low energy density region (LEDR) pink marker. 
 
 
75 
  
Chapter 1 Figure 24: Sample screen showing the calculated volume of tissue to be treated and the number of treatment 
spots required.
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Chapter 1 Figure 25:  Sample screen showing treatment consisting of multiple sonications to ensure tumour ablation. 
Real time thermal maps give the operator feedback on treatment efficacy.
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Treatment outcome 
 
At the end of treatment contrast enhanced MR images are acquired to measure the 
degree of contrast agent uptake. Regions without contrast agent uptake (non-
perfused) have been destroyed by the thermal effects of the focused ultrasound. 
The physician can determine whether sufficient tissue has been treated, or if a 
repeat treatment is necessary (see figure 26) 
                              
                             
                  
Chapter 1 Figure 26. Top image shows coronal view of the accumulated 
thermal dose. The lower contrast enhanced image shows the non-
perfusion achieved which correlated exactly to the treated regions. 
 
Area of non-perfusion 
Accumulated thermal dose 
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CHAPTER 1.4:  PRELIMINARY CLINICAL DATA ON 
MRgFUS 
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1.4.1 Safety and Feasibility 
 
The initial clinical trial assessing the safety and feasibility of MRgFUS in the 
treatment of clinically significant uterine fibroid (UF) was conducted in five 
centres in the United States, Britain, Germany and Israel (Stewart, Gedroyc et al. 
2003). A total of 55 patients were treated in this study.  The study was designed to 
assess treatment-related pain and complications prospectively and utilized post-
treatment MR imaging to assess treatment effects.  At three of the five centres, 
patients underwent planned hysterectomy following the MRgFUS procedure, 
enabling a correlation between pathologic and clinical outcomes. 
 
Participants were at least 18 years of age and had no plans for future pregnancy. 
Subjects with a uterine size >20 weeks of gestation or a dominant UF >10 cm 
diameter were excluded from the study. Treatment time was planned for less than 
two hours. 
 
Of the 55 patients enrolled the study, 15 (76%) completed the full treatment 
session. Three patients received no treatment due to the presence of bowel in the 
beam path that could not be remedied.  Ten other patients received less energy 
than prescribed in the treatment plan.  In most cases this was due to an inability to 
detect the low-energy test pulse, which resulted in a failure to administer a 
therapeutic sonication. This was typically caused by the presence of surgical scars 
or variations in the deposition of fat and muscle within the abdominal wall.  
 
Discomfort was minimal, and no major complications were reported. Thermal 
injury in the adjacent normal myometrium was observed in only one patient, and 
is believed to have resulted from a change in the position of the target tissue due 
to filling of the patient’s bladder during the treatment session. Only 10% of 
patients with 72-hour follow-up data reported use of pain medication. At the 72-
hour visit, the physician observed abdominal skin burns in two patients, which the 
patients themselves had not reported.   
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MR imaging with gadolinium immediately following MRgFUS treatment 
revealed that there was a modest but statistically significant increase in the non-
perfused volume compared with the treatment volume (20.0 ±3.2 ml vs. 34.6 ±6.2 
ml, P< .004). Patients undergoing hysterectomy underwent additional contrast-
enhanced MR imaging at 72 hours post-treatment, and the difference was greater 
at this time point (6.5 ±0.8 ml vs. 22.6 ±4.3 ml, P< .002). The extension of the 
effective treatment volume was confirmed by pathologic examination of uterine 
tissue in patients undergoing hysterectomy. 
 
1.4.2 Phase II  
 
The efficacy of MRgFUS was assessed in a Phase II clinical trial of 35 patients 
with symptomatic UF who were scheduled for hysterectomy (Hindley, Gedroyc et 
al. 2004). The study design included prospective analyses of clinical symptoms, 
patient satisfaction and uterine size 1 month and 6 months after undergoing 
MRgFUS.  Study participants had a uterine size of <20 weeks’ gestation and 
dominant fibroid size <10 cm in diameter.  Treatment was targeted to one or two 
fibroids in each patient.  All procedures were performed on an outpatient basis, 
and patients were discharged after approximately two hours of post-treatment 
observation. 
 
A total of 41 fibroids were treated in the 35 study participants.  Mean pre-
treatment volume of these fibroids was 216 r 223 ml, and the mean treated 
volume was 18 r13.3%.  Mean post-treatment NPV was 53 r 94 ml, 
corresponding to a mean of 31 r 23% of the pre-treatment volume.  Of the 35 
patients, adequate ablation of target tissue was not achieved in four due to 
technical problems.  Three of these four patients opted for hysterectomy.  Two 
patients who received adequate ablation based on the treatment protocol also 
opted for hysterectomy due to continued UF symptoms.   
 
Twenty-one patients underwent MR imaging studies at 1-month post-MRgFUS. 
At this time point, the mean fibroid volume reduction was 12 r 16%.  A marked 
increase in UF size was observed in one patient.  MR imaging studies were 
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conducted in 29 patients 6 months after MRgFUS, at which time the mean fibroid 
volume reduction was 15 r 27 compared with the mean volume of all 35 patients 
on the day of treatment. Fibroid volume was markedly increased in one patient at 
this time point as well Marked or partial improvement in UF symptoms was 
reported by 37.1% and 31.4% of patients, respectively, in the six months 
following the MRgFUS procedure. 
 
In the 6 months after MRgFUS, six patients (17%) opted for hysterectomy due to 
continued UF symptoms.  Two of these six had not received adequate ablation, 
and two others had uterine adenomyosis rather than fibroids. In one additional 
patient, there was a volume reduction in the two treated fibroids, but six untreated 
fibroids increased in size. 
 
No major short- or long-term side effects were reported.  Minor reported side 
effects were a small skin burn on the abdomen that resolved within two weeks and 
transient sciatic pain that resolved after one week. Minor and transient lower 
abdominal pain, which resolved shortly after MRgFUS, was reported by several 
patients.  
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CHAPTER 1.5: MEASURES OF TREATMENT OUTCOME 
FOLLOWING MINIMAL INVASIVE TREATMENTS 
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There are many ways to assess the efficacy of fibroid therapy. Clearly the simplest 
is complete resolution of symptoms after definitive surgical removal of the entire 
uterus and all fibroids, as in a hysterectomy. However,with the development of 
lesser invasive treatment alternatives to hysterectomy, that do not completely 
eliminate the fibroid, the need for patient– reported outcomes to assess symptom 
reduction has arisen.  
 
The patient’s subjective response along with physical and imaging findings can be 
evaluated in total. The classic way to assess outcome has been to assess the size 
and volume of the uterus. Early studies often did this with unblinded examiners by 
pelvic exam, which clearly made understanding the real treatment effects difficult. 
However, with the use of GnRH agonists in the 1980s and 1990s, the use of US 
volumetric measurements was introduced. This is a powerful technique since a 
relatively small change in a measure diameter can result in a significant difference 
in the volume. However, for this reason, it is also prone to error, because small 
differences in measurement can appear to produce significant differences in 
volumetric analysis. Additionally, volume reduction is not always necessary or 
helpful in terms of reducing symptoms. Some women with uterine fibroids have 
only symptoms of heavy menstrual bleeding, and a volume reduction does not 
predict clinical success. It has therefore, become increasingly important to find a 
tool which provides an evaluation of the clinical success of uterine-sparing 
therapies chosen by patients.  
 
The published data on Health Related Quality of Life (HRQL) associated with 
uterine fibroids consistently report a lower quality of life for women with fibroids 
(average score 62) than for women without (average score 86). The Uterine 
Fibroid Symptom and Health Related Quality of Life Questionnaire (UFS-QOL) 
is a uterine fibroid specific questionnaire developed by Spies et al (Spies, Coyne 
et al. 2002) to evaluate the symptoms of uterine fibroids and their impact on 
HRQL.  
 
The UFS-QOL has been used in studies of various fibroid treatments, including; 
UAE (Smith, Upton et al. 2004; Scheurig, Gauruder-Burmester et al. 2006; Siskin, 
Shlansky-Goldberg et al. 2006), radiofrequency thermal ablation (Bergamini, 
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Ghezzi et al. 2005; Ghezzi, Cromi et al. 2007) MRgFUS (Stewart, Rabinovici et 
al. 2006) and treatment with medication. consisting of eight symptom questions 
and twenty nine health related quality of life questions, the questionnaire was 
derived from focus groups of women with leiomyomata. A total of 110 patients 
with confirmed leiomyomata and 29 normal subjects participated in the 
validation. Among the instruments used for the validation were the short form-36, 
Menorrhagia Questionnaire, R-W sexual function scale, and a physician and  
patient assessment of severity. 
 
The final questionnaire accurately  discriminated not only from controls, but also 
from patients with varying degrees of symptom severity (see figure 27). 
Maximum symptom severity score is 100 with a higher score indicating greater 
severity of symptoms. A drop of 10 points in the scoring indicates significant 
improvement of symptoms as reported by Spies et al (Spies, Coyne et al. 2002). 
This questionnaire has been utilised throughout this work as a tool to measure 
treatment outcome, wherever symptom improvement was a primary outcome. 
 
 
 
Chaper 1 Figure 27: This graph compares the average symptom severity 
score in 3 groups of women; those without fibroids, those with and those 
treated in the pivotal group. It can be seen that this group of women are 
highly symptomatic when compared to those with no fibroids. 
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2.1 Patient assessment 
 
All Patients were recruited from the tertiary fibroid clinic. Patients were either 
referred by their general practitioner or by a gynaecologist for assessment and 
treatment of uterine fibroids.  
Each patient was seen by a clinical research fellow (SZ) who obtained the 
patient’s medical history specifically focusing on gynaecologically significant 
symptoms and assessed uterine fibroid symptoms according to the UFS-QOL 
questionnaire a validated health and symptom related questionnaire specific to 
uterine fibroids (see chapter 1.5 for more details).  A clinical examination was 
performed, in particular of the abdomen to assess uterine size and inspection for 
any scars 
 
A full blood count was taken to measure hemoglobin levels. Patients’ eligibility 
was assessed according to the inclusion-exclusion criteria listed in the Ex-Ablate 
commercial treatment guidelines (see table below). In general, Patients were 
excluded, if they had contraindications for MR imaging such as non-MRI 
compatible implanted metallic devices. Patients deemed unable to comprehend 
instructions or communicate sensations during treatment were also excluded, as 
safe treatment relies on the ability of the patient to communicate sensations such 
as leg, buttock, and skin or back pain to the operator.  
 
If the patient was clinically eligible and interested in MRgFUS, she was then 
referred for a screening MRI scan. 
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Patient Exclusion Criteria 
 
1. Haemoglobin <10 
2. Patient has haemolytic anaemia 
3. Patient has unstable cardiac status including:  
 Unstable angina pectoris on medication 
 Documented myocardial infarction within 6 months of protocol entry 
 Congestive heart failure requiring medication (other than diuretic) 
 Currently taking anti-arrhythmic drugs 
 Severe hypertension (diastolic BP>100 on medication) 
 Presence of cardiac pacemaker   
4. Patient has severe cerebrovascular disease (multiple CVA or CVA within 
6 months) 
5. Patient is on anti-coagulation therapy or has an underlying bleeding 
disorder  
6. Evidence of uterine pathology other than leiomyoma 
7. Patient has an active pelvic infection  
8. Patient has an undiagnosed pelvic mass outside the uterus. 
9. Patient weight >110 kg 
10. Patient with extensive longitudinal abdominal scarring in an area of the 
abdomen directly anterior to the treatment area. 
11. Patient with standard contraindications for MR imaging such as non-MRI 
compatible implanted metallic devices.  
 
12. Individuals who are not able or willing to tolerate the required prolonged 
stationary prone position during treatment (approximately 3 hours.)  
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2.2 Screening MRI Scan 
Screening is performed in the prone position, and consists of three orientations 
including both T2 weighted images and T1 weighted images before and after 
gadolinium injection. A radiologist experienced in MRgFUS analyses the 
screening MR images to determine patient suitability for the procedure. 
 Patients are deemed technically suitable for MRgFUS if their fibroids 
mass seemed accessible by the system and treatable in a reasonable time.  The 
majority of the fibroids mass should be no more than 12 cm depth away from the 
skin line, as this is the upper limit of the system. Patients with bowel that could 
not be shifted from the potential beam path were also excluded from 
consideration, as air bubbles or hard particles present in the bowel may reflect or 
absorb the ultrasonic energy. Patients with more than six uterine fibroids of more 
than 4cm size each were excluded, as usually in these cases some of the fibroids 
will be close to the sacrum or hidden behind bowels thus will be inaccessible. 
Patients with longitudinal scars in the beam path, including those that could not be 
seen on the MR images, also were excluded, as scar tissue may absorb the 
ultrasound energy and cause pain or even a skin burn. Other factors for exclusion 
are calcified fibroids, which ultrasound energy cannot penetrate into; patients with 
non-enhancing fibroids that are already dead; pedunculated fibroids, that might 
disconnect after the treatment into the abdominal cavity; and patients with 
pathologies other than uterine fibroids, such as adenomyosis. 
 Patients who have total fibroids volume of more than 500cc, or a hyper-
intense fibroid on T2 weighted imaging were pre-treated with a GnRH analogue 
for three months in an effort to reduce the size and vascularity of the fibroid. 
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2.3 MRgFUS Procedure 
All MRgFUS procedures were performed using the ExAblate 2000 (InSightec, 
Haifa, Israel), which is fully integrated with a 1.5 Tesla MR scanner (GE Medical 
Systems, Milwaukee, WI). 
 
Patient Preparation 
Informed consent was obtained from all patients prior to proceeding to treatment. 
The procedure is performed as a day surgery or outpatient treatment; the patient is 
asked to remain fasted for a minimum of 4 hours, and is then prepared before 
entering the magnet. Preparation involves insertion of an intravenous line and 
Foley catheter. Examination of the abdominal wall for the presence of scars and a 
check to ensure complete shaving of the pubic area is essential to prevent the 
occurrence of skin burns. The patient receives a light sedative and analgesia as 
requested throughout the procedure. The regimen used comprises of a maximum 
dose of 10mg of diazemuls, with a starting dose of 20mg; a maximum of 100 mg 
of pethidine with a starting dose of 20 mg, and 1g of paracetamol given as an 
intravenous infusion started. This regimen allows the patient to be relatively pain-
free, comfortable, awake and responsive throughout. At all times the patient’s 
pulse and oxygen saturations is monitored using a pulse oximeter. 
 
The MRgFUS treatment step by step 
Turning on ExAblate 2000 Console 
 Turn on by pressing the green power on button on the console 
 When the system is ready type in the username and password 
 Press OK and ensure that the username and password have been accepted. 
 At this point the system will; 
 Power up the treatment table (indicated by the light on the quick coupling 
cable) 
 Start up the cooling system and allow it to reach the set temperature value 
 It will run checks on the transducer’s motion 
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Setting up the Treatment Table 
 
 Ensure that the LED on the quick coupling cable is green, if not, return to 
the ExAblate console and ensure that the system has started up.  If you are 
still having problems discuss with a senior FUS trainer. 
 
Visual inspection of equipment and attaching anterior coil  
 
 Detach the Anterior coil part from the table 
 Remove the protective membrane cover off the transducer bath. 
 Visually check the integrity of the of the table looking for any loose 
fittings or cracks 
 The transducer bath should be free of air bubbles and leaks. 
 Ensure that the Mylar surface is not damaged and free of any dust or any 
other small particulates as these can create air bubbles when setting up the 
treatment bath.  
 Connect the anterior segment of the imaging coil to the treatment table 
with the two clips and ensure that is secure. 
 
Positioning Patient Comfort pads  
 
 Directly on the treatment table there is a pad that is shaped to fit the 
inferior part of the table, and another for the superior part, ensure that both 
pads are correctly positioned.  
 The patient comfort pad is then placed directly over the table so the 
opening is directly over the transducer bath. 
 To ensure that the treatment bath will be deep enough to contain enough of 
the water. Put a large triangular pad just inferior to the treatment coil and 
smaller pad at the superior end of the opening. 
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Creating Treatment Bath 
 
 Mixing Gel and Water to produce Coupling Substance  
 Squeeze out about a third of the Ultrasound gel sachet onto the Mylar then 
add a splash of water (10-15mls) then mix.  This should produce a thin 
film on the mylar. 
 Place plastic membrane on mylar sheath 
 Open the plastic membrane and carefully open it ensuring that no extra 
creases are added to its surface. 
 Visually locate the centre of the sheet and then place this in the centre of 
the transducer bath 
 push the membrane so it is in contact with the mylar surface 
 Pour enough water onto the membrane to at least cover the anterior 
segment of the imaging coil, the water provides a weight to help anchor 
the membrane to the mylar surface. 
 
 Secure Sheet to Patient Comfort Pad and Anchor 
 Secure the edges of plastic membrane to the patient comfort pad 
approximately 5cm from the opening, this provides an anchor for the 
outside of the membrane while providing plenty of extra plastic so that the 
membrane may move while the patient is being positioned  without 
compromising the integrity of the acoustic coupling. 
 
 Use the Plastic Card to remove any bubbles and excess gel water mixture  
 Use the edge of the plastic card provided in the treatment kit to gently 
push bubbles out  
 Using movements from the centre to the outer edge of the bath. 
 Pressure used should be enough to remove excess gel and any air bubbles 
to produce a close contact between the plastic and the mylar without 
displacing all of the gel. 
 Visually check the plastic/mylar interface to ensure that there are no 
bubbles and the gel/water mixture is of an even consistency.  Fine lines in 
the interface indicate that there is no gel/water mixture in this particular 
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area this could lead to air bubbles occurring during the treatment which 
could lead to equipment damage, therefore this interface must be redone.  
 
Positioning coupling gel pad in treatment bath 
 
 Carefully remove the gel pad from the container ensuring that either 
surface of the pad is not damaged. 
 Slide the gel pad into the bath ensuring that there is no air between the 
plastic and the pad. 
 Gently press the pad down to ensure it is right against the plastic/mylar 
interface. 
 Ensure that the surface of the water in the bath is above the gel pad.  
 
Positioning DQA Phantom on treatment pad 
 
 The DQA phantom is solid water based crossed linked gel. It can be used 
for multiple quality assurance tests, however it is fragile so careful 
handling is required to maintain its integrity.   
 Remove the DQA Phantom from plastic container by opening the cover 
and tipping the container upside down onto an open hand.  
 Inspect it for major flaws, if there are any dispose and replace. 
 Slide onto treatment pad, so that it is in the middle of the gel pad over the 
transducer 
 Don’t use excess pressure as the phantom may leave an imprint on 
treatment pad 
 
 Positioning Support and Posterior Coil 
 
 Place the clear plastic support over the phantom so that the posterior coil 
can be draped over it. 
 Position the wings of the patient comfort pad under the ends of the coil. 
 Inspect the flexible MR coil for cracks in the insulating plastic and ensure 
the gold connectors within the plug are visible.  
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 Be careful when plugging in anterior coil, if the coil is seated incorrectly 
or excessive force is used the gold connectors within the plug will be 
damaged, resulting in loss or no signal from the posterior coil and in-turn a 
reduction of image quality.      
 Raise the table and plug the anterior coil into the scanners connector port. 
 Landmark to the white line on anterior coil, this indicates the centre of the 
water bath.  If the landmark is not centred to this point the transducer 
template will not appear on the calibration images. 
 When the table is moving into iso-centre ensure all cables are free of 
obstructions. 
 
Performing Quality Assurance 
 
 On the HDx Workstation in the scanning window select “new MR Exam”  
 Click in Patient ID text box and type “FUS DQA” and press enter 
 A dialogue box will pop up, select “first level” then select “Accept” 
 Press enter until you get to Patient’s Weight type in 50kg and present 
enter. 
 In the protocol section select Pelvis 
 Select protocol P18. FUS DQA 
 Select Save Series 
 Select Scan 
 The MRI scanner will perform one coronal image at posterior 30, which is 
the centre of the QA Phantom. 
 This is performed for two reasons; 
 It provides an image in the centre of the phantom to allow the region of 
treatment (ROT) to be planned 
 At least one image needs to be performed on the MRI System to provide 
the ExAblate system with the patient’s entry and position. 
 
Selection of Treatment Option and Beginning Treatment 
 
 The status bar on the ExAblate start window should show that the Device 
and the MR Scanner ready.  
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 Select Uterine Fibroid as the treatment option,  
 Select the Treatment Button to begin the treatment session. 
 The system will then load the specific application required for treating 
fibroids. 
 In the Physicians name text box, type “QA” and click OK  
 The System will then open up the Calibrate Screen 
 
Calibrate Stage 
 
 This is the first stage of the ExAblate 2000 treatment procedure 
 The Calibrate stage provides the system with the necessary information to 
determine the transducer’s home position and orientation. 
 
 Scanning Calibration Images 
 
 Click MR Scan  
 A pop-up message will appear on the operating console screen, check and 
confirm the patient’s name and position is correct. 
 The MR Scanner will then perform scans in the sagittal and axial planes. 
 
 Check the Acoustic Path 
 
 While the scans appear on the HDx Console Display window examine 
each image along the entire acoustic path ensuring that there are no air 
gaps visible.  If there are any air gaps visible between any of the layers 
appropriate repositioning should be preformed. 
 
 Localising the Transducer 
 
 Once these scans are completed they will appear in the image strips. 
 The transducer template is displayed as a yellow overlay; it will be in the 
positioned in the transducer’s last home position. 
 Click on the sagittal image with the transducer template so it appears in 
the selected image window.  
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 Adjust the display window and level so that the outline of the transducer 
on the image can be seen accurately  
 On the sagittal image click on the transducer template and drag the 
transducer template so that it overlaps the transducer image. 
 Ensure there is no pitch on the transducer image, if there is click on a 
corner of the transducer template and adjust accordingly.  
 Click on the axial image with the transducer template so it appears in the 
selected image window and adjust the display window and level as done 
previously.  
 Adjust the transducer template on the axial image if necessary. If there is a 
roll on the transducer image, click on one of the corners of the transducer 
template and adjust accordingly.  
 
Calibration 
 
 When the transducer templates are in place click the Calibrate button to set 
the transducers home position. 
 A message will appear asking whether you wish to accept this as home 
position. 
 
 
Load stage 
 
 Click Load on the main toolbar to advance to the next stage 
 Load Stage allows the selection of the MR images required for treatment 
planning, once selected these images are transferred from the MR to the 
ExAblate System. 
 Any QA or treatment requires images in all three planes to be acquired, the 
initial localiser provides the coronal image, and the two transducer 
calibration series provide the sagittal and axial images. 
 Check that the Exam No. corresponds to the current exam. (The “Show 
only last exam” should ensure this is the case) 
 Click on the coronal image in the series list and click Select all 
 Check that series appears in the “planning images” section of the screen 
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 Repeat the last two steps for the sagittal and axial images respectively. 
 If you wish to change the images selected click clear and select a different 
set  
 Once all three planes are loaded then click on draw on the main toolbar to 
advance to the next stage. 
 
TREATMENT  
 
Positioning the Patient 
 Consider the patient’s weight and distance from the inner dimensions of 
the magnet, to avoid obstruction of the table.  
   
Acquiring Planning Images 
 After the localiser is performed run through the images and check, 
 1. That the region to be treated is directly above the transducer. 
2. Confirm whether bladder or rectal filling is required the Sagittal T2 
images may help you decide     
 T2 weighted images are obtained in the coronal, axial and sagittal planes 
 Examine the images and ensure that; 
1. They clearly identify the region of treatment (ROT) or fibroid(s) to be 
treated. 
2. They include the entire path from the skin to the target area (Sagittal & 
Axial). 
3. There are no air gaps visible along the entire acoustic path from the 
transducer to the lesion. 
4. The patient has not moved during the imaging  
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 Load Stage 
 
Downloading previous images (This is particularly useful for patients having 
second treatments) 
 If the patient has had previous treatments it is possible to load the previous 
post-contrast images to aid in defining the new region of treatment. 
 Ensure you know the exam and series numbers of the images you wish to 
download 
 Click show all exams 
 Select the exam number from the list all of the series in that exam will 
appear in the series list. 
 Select the series number click Select All 
 The images will then appear in the planning to prior image list. 
 Repeat last two steps until all of the images you wish to include are 
loaded. 
 
Continuing Treatment in Case of Movement  
     
 If patient movement is detected during the treatment and new planning 
images are required, perform registration between the new images with the 
original planning images in order to preserve the dose volume 
accumulated up until the current point. 
 Click planning to prior  
 The system will warn you that some of the data will be lost. 
 All planning images will appear in the prior images frame. 
 Once the new images have been acquired click refresh to update the MR 
exam 
 Select the new planning images as done previously. 
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Draw stage 
 
In this stage, the operator defines the Region of Treatment (ROT), selects the 
treatment protocol, draws the skin line, draws Limited Energy Density Regions 
(LEDR) and places fiducial markers (red crosses). 
 
Creating or selecting the ROT 
 
 To create a new ROT click the button labelled ROT and select new ROT.  
 ROT’s are drawn on the coronal image. In order to identify the coronal 
image to draw on, the sagittal image can be used to find the maximum 
diameter of the target lesion. 
 Once you have selected the image, in the selected image window click on 
the target lesion to start the ROT outline. 
 Move the cursor in one direction, clicking on successive points to create 
the ROT outline. 
 Click as many points as required to create a rough circumferential lesion. 
The accepted practice is to leave a 5mm margin from the edge of the 
targeted lesion. 
 The ROT can be moved if adjustment is required by clicking and dragging 
it. The ROT can be deleted by clicking on it and pressing the delete button. 
 
Treatment protocol 
This selects the protocol under which the treatment will proceed. This then sets 
pre-determined spot sizes and the energy and power to be used to treat. These 
parameters can be adjusted later by the operator during the treatment stage, 
dependent on thermal feedback received.  
Click on the button and select UF nominal from the drop down menu. 
 
Defining the skin line 
 Select and click on an image approximately at the centre of ROT (outlined 
in yellow), where the skin line is clearly visible. Match this coronal image 
to its equivalent axial image 
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 Click the Define skin line button. 
 Click at the start of the skin line and click at multiple points, making sure 
you are clearly marking along where the skin line is. 
 Double click to finish. 
 To edit a drawn skin line, click on a segment and drag it to the desired 
location. 
 
Defining the Limited Energy Density Regions (LEDR) 
 
 There are 3 LEDRs. These are the bowel, pubic bone and far field bone. 
The definition of both bowel and pubic bone LEDRs is performed on the 
Sagittal view. The definition of the far field bone LEDR is performed on 
the Axial view. 
 
Pubic Bone 
 
 Click on a Sagittal view where the pubic bone LEDR is clearly visible. 
The image will appear in the selected image window. 
 Click on the define LEDR button and from the pull down menu select the 
type of LEDR which is pubic bone. 
 Draw the LEDR contour around the pubic bone in the selected image, 
double click to finish. The contour should be in the rough shape of a 
parabola completely shielding the pubic bone.  
 The contour around the LEDR needs to be drawn only on every other 
image. 
 Ensure that in the images where the catheter tip and balloon appear, that 
these are also drawn round. Both the catheter tip and the balloon are 
LEDRs. 
 By using the interpolate feature button, the graphic elements will be 
interpolated on all slices. 
 Click through each slice to ensure that the interpolation feature has worked 
and that the contour line can be seen and is accurately covering the LEDR. 
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Bowel 
 
 Bowel is a LEDR and the contours are drawn on the sagittal images.  
 Click on the define LEDR button and from the dropdown menu select 
intestine. 
 In the same way draw a contour round the bowel, the drawn line should be 
all the way down the front of any visible bowel, with a small flick at the 
back. The contour line should look like a back to front tick. 
 In the same way every other slice must be drawn on. 
 Click on the interpolate feature, to interpolate the contour line on every 
image 
 This step must be checked with a radiologist before proceeding. 
 
Far Field Bone 
 
 Far field bone is considered a LEDR. This is because as bone heats up 
during treatment, temporary nerve damage (neuropraxia) can occur. 
 Contours are drawn on the axial image. 
 Click on the define LEDR button and from the dropdown menu select far 
field bone. 
 In the same way draw a line round the contours of the cortical bone in the 
beam path making sure to include every slice where nerves are present. 
 For far field bone, contours are drawn on every slice.  Therefore 
interpolation is not required. 
 After drawing the bone cortex contours, make sure that they are fully 
defined in the entire acoustic pass zone. 
 
Drawing fiducial markers 
 
 The purpose of these markers is to facilitate detection of patient 
movement. 
 Click on the fiducial button and point and click to add a fiducial marker on 
an anatomical feature as a reference marker. 
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 Fiducials must be placed around the uterus and bladder if filled, bony 
landmarks are useful reference points also. 
 Monitoring patient movement is important in order to ensure accurate 
sonication targeting. 
 Monitor the fiducial markers during the course of the treatment. This is 
particularly important if the catheter is clamped, as urine collection in the 
bladder will lead to alteration in the planned images. 
 
 
Plan Stage 
   
In the plan stage the system calculates and displays the treatment plan intended to 
cover the tumour surface in the ROT, and automatically determines the beam 
incidence angle of each one of the sonication spots to be as perpendicular to the 
tumour surface as possible. 
 
During this stage the operator edits and confirms the treatment plan.  
 
 Optimise the treatment plan such that there are no sensitive organs in the 
pass zone, and all spots are green  
 Examine the treatment plan in all orientations; verify that the sonication 
spots cover the target tissue. 
 If necessary individual sonication may be edited by selecting the 
individual spot and either angulating or changing the parameters until the 
spot becomes valid.  
 Multiple spots may be selected by pressing the multiple arrow button. 
 Remember that changing the sonication location, tilt or acoustic 
parameters will influence its predicted dose and hence its size and 
location. Carefully examine each sonication after such a change is 
perfomed. 
 Before advancing to the verify stage, go into the room, to instruct the 
nurse and patient that you are about to start sonication. Go through use of 
the patient button with the patient and ensure they know when to stop 
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sonication. Any sensations of leg, back, buttock or skin pain must be 
relayed to the nurse or the present physician. 
 
 
Verify Stage 
  
Geometric verification- this ensures that the actual ablated spot is in fact the same 
as the planned target spot. Only sub-therapeutic doses are used to avoid injury at 
this stage. 
 
 
The verify stage must be successfully completed before continuing onto the 
treatment stage. 
 
The information window 
 
The Reflection Data tab shows the result of the reflection measurement performed 
prior to each sonication. Any pulse appearing in the graph, above the dashed 
horizontal line, represents a significant reflection from a surface. The surface 
causing the reflection is located a distance from the transducer as shown in the 
reflection plot. When this occurs, stop the treatment and improve the acoustic 
coupling (checking for air bubbles is essential). 
 
The Spectrum Data tab shows the spectrum graph, which helps to detect the 
presence of cavitations. A spectrum with high shoulders above the dashed 
horizontal line may indicate the presence of cavitations. When this occurs, stop 
the treatment and continue with a lower sonication energy. 
 
 
The Geometric verification procedure 
 
 Select the ROT to perform the verification spot. 
 Click the add sonication button and add a reference sonication spot in the 
selected image window. 
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 Verify that the sonication test spot is located within the ROT 
 Verify that the spot pass zone is not passing through any LEDRs, the 
system will warn you if the spot is invalid e.g. it is too close to the skin 
line, far field bone, pubic bone or bowel. 
 The system automatically defines sonication parameters for geometric 
verification.  
 
 Ensure the patient is comfortable and let them know you are about to 
begin. 
 
 Click the sonicate button to apply the ultrasound energy. 
 
 The sonication starts with the MR scanning images and then starts 
transmitting     ultrasound energy. 
 
 During the sonication, you should be monitoring, patient discomfort, 
reflection signal, spectrum signal during the transmission of energy, any 
patient movement by observing fiducials and the evolving temperature rise 
during sonication. 
 
Geometric Adjustment 
 
 On the thermal map, verify that the spot is within 1mm of the planned 
location. If it is repeat the procedure in the Sagittal view. At this point you 
may increase the energy to 130% to build up the patient’s tolerance of the 
procedure. 
 
 If the hot spot is over the 1mm margin, click the adjust button and click in 
the centre of the hot spot to adjust to the correct position. The adjust 
function automatically corrects the transducers position according to the 
offset between the sonication location and the planned spot location. A 
pop-up will appear asking you accept the adjustment. Click apply, and 
then discard the measured thermal dose and continue. 
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 If a hot spot is not acquired it may be that insufficient energy was applied, 
increase the energy by 10% increments and repeat the procedure, until a 
hotspot is seen. 
 
 After the spot is aligned in both Sagittal and coronal orientations, you can 
advance to the treatment stage. 
 
Treat stage 
 
During the treatment stage the full therapeutic sonication energy is used and all 
planned ROTs are treated. Throughout the process the operator can change the 
treatment plan and the sonication parameters, according to the continuous 
feedback being received. This is the concept of the closed loop therapy system. 
 
The treat stage elements are similar to the verify stage, but with use of full 
therapeutic dose energy. 
 
The Treatment Procedure 
 
 Verify that the patient is comfortable. 
 
 Examine the next spot to be sonicated, this is picked automatically for you 
by the system. The Interleave application which is on automatically, 
allows the system to select spots on the basis of reducing cooling time. 
Therefore the system selects the furthest spot from the current sonication 
as the next target. 
 
 When highlighted in blue, this means that this is the current spot to be 
treated and it is valid. When highlighted in yellow, exercise caution when 
trying to optimise the location and/ or orientation. Check the parameters 
and assess if the clinical situation allows this sonication. Information on 
why the spot is not blue is displayed in the information box at the top-right 
side of the screen. 
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 Based upon the examination of the actual dose and patient feedback, 
manual changes to the treatment plan are possible at any stage during a 
treatment. Sonication parameters such as the energy, duration and 
frequency may be altered. Spots may be added or removed. Spots may be 
angled to avoid spot pass zone passing through LEDRs. 
 
 Remember if there is a need to stop the soincation process press the STOP 
SONICATION button. This button remains depressed and requires to be 
manually pulled back to start position. 
 
 Before each sonication, ensure that fiducials are placed around the entire 
target organ the uterus and NOT the fibroid/ ROT. Verify that there are no 
sensitive organs in the pass zone. Verify that the cooling system light is 
illuminated continuously and not blinking.  
 
 Once all parameters have been checked click the Sonicate button to apply 
the ultrasound energy. During the sonication, you must monitor 
o Patient discomfort 
o Reflection signal 
o Spectrum signal 
o Patient movement by checking the fiducial markers on the MR 
magnitude images. 
o The evolving temperature rise during sonication. 
 
 After the sonication, evaluate the thermal map, check the temperature at 
the skin line by dragging the cursor to various points along the skin line. 
Temperature at the skin line must be below 45 degrees. 
 
 Click continue, to the next sonication or to repeat the last sonication the 
repeat sonication button can be clicked. Do not forget to click back onto 
the next sonication button. To continue the treatment, accept the measured 
does of the last sonication.  
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 Repeat the procedure until all the planned sonications have been 
performed. 
 
 If the patient moves or is repositioned, you must return to the load stage, 
scan new planning images, load these and create a new treatment plan 
based on these images. 
 
Conclusion of Treatment Session 
 
At the conclusion of the treatment session, a post treatment contrast enhanced 
assessment is performed to identify the non-perfused or ablated volume. This 
identifies treatment success. A series of 3 sagittal scans are performed, 1 axial and 
coronal, following administration of 10 ml IV gadolinium. A post FUS treatment 
protocol can be found in the drop down menu. 
 
 
 
2.4 Post-treatment recovery of patient 
 
Upon completion of the post treatment contrast scans, the patient is assisted off the 
table and the skin must be checked to exclude superficial ulceration/burns. In the 
recovery room, the patient’s observations; pulse, blood pressure and oxygen 
saturations are taken. The urinary catheter and intravenous cannulae are removed. The 
patient is allowed a meal and is observed for 1-2 hours until total consciousness is 
regained. The patient is advised to avoid driving for 24 hours and long haul flights for 
48 hours. 
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CHAPTER 3: PATIENT SELECTION CRITERIA FOR 
MRgFUS AND MITIGATING TECHNIQUES TO INCREASE 
PATIENT SUITABILITY  
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Summary 
The aim of the study was to assess selection criteria used to determine patient 
eligibility for proceeding with magnetic resonance-guided focused ultrasound 
surgery (MRgFUS) for the treatment of symptomatic uterine fibroids. It was 
aimed to also assess the percentage of patients presenting to a general fibroid 
clinic suitable for MRgFUS. The hypothesis of this study was that by identifying 
mitigating techniques we could increase the number of women that the non-
invasive technique of MRgFUS could be offered to. 
 
This was a retrospective analysis of 144 patients seeking minimally invasive 
treatment options for symptomatic uterine fibroids at a single treatment center. 
Clinical eligibility for MRgFUS was assessed at a gynaecology clinic by S. Zaher, 
a gynaecology research fellow trained in the procedure and suitability was 
assessed by magnetic resonance imaging. Several techniques were used to 
mitigate against factors that are contra-indications for MRgFUS. 100% of patients 
interested in MRgFUs were deemed clinically eligible for the procedure and 74% 
were deemed technically suitable to proceed with treatment.   
 
It was found that mitigation techniques allow for less restrictive MRgFUS 
selection criteria for treatment for symptomatic uterine fibroids.  These less 
restrictive criteria are expected to expand the pool of patients for whom MRgFUS 
is a viable treatment option for uterine fibroid symptoms. 
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Introduction 
 
Previous experience with UAE has shown that a key factor in the acceptance of 
novel treatment options for uterine fibroids is the development and dissemination 
of consistent and informative patient selection criteria. The patient selection 
criteria for UAE are now well known and include both relative and absolute 
contra-indications. Absolute contra-indications for UAE include: a viable 
pregnancy, pedunculated fibroids, active infection and a suspicion of malignancy. 
Relative contra-indications include: coagulopathy, renal impairment, the desire to 
maintain child-bearing potential, and the concurrent use of a Gonadotrophin 
Releasing Hormone (GnRH) analogue. 
 
Our centre at St Mary’s Hospital, Paddington, was one of the first world-wide to 
utilize MRgFUS, performing the procedure in up to 500 women with symptomatic 
uterine fibroids. Based on our institution’s extensive experience using MRgFUS 
in the treatment of symptomatic uterine fibroids we have developed selection 
criteria that are designed to maintain the safety and efficacy of the technique, 
whilst also making it available to as many patients as possible. The aim of this 
study was to assess the selection criteria used to determine eligibility for 
MRgFUS and to assess the percentage of patients who are suitable for MRgFUS. 
 
Initial guidelines on patient selection criteria were provided by the manufacturer 
(Insightec Ltd) and were decided and approved by the Food and Drug 
Administration (FDA). With further experience these guidelines were found to be 
more restrictive than those needed for the updated MRgFUS system in use in our 
centre and many limitations could be overcome, by various mitigating techniques.  
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Patients and Methods 
Patient Population 
Patients attending the tertiary fibroid clinic at St. Mary’s Hospital between 
September 2005 and December 2006, and who specifically expressed interest in 
minimally invasive treatments for their fibroids, were included in this 
retrospective analysis. The patients were referred by their general practitioner or 
by a local gynaecologist.  For demographics see table 1 below. 
Patient Demographics  
N=100 
Age (years)  
 Mean (Years) 42.8 
Range (Years) 22 – 57 
BMI (kg/m2)  
 Mean 24.9 
Range 19 – 38 
Hormonal Status  
 
 Pre-menopausal 89% 
Peri-menopausal 11% 
Race 
 White 48% 
Asian 12% 
African 40% 
Number of fibroids 
 Patients with a single fibroid 61% 
Patients with multiple fibroid 39% 
Fibroids intensity on T2w images (relative to myometrium) 
 Patients with hyper-intense fibroids 12% 
 
Chapter 3 Table 1: Potential MRgFUS Patient Demographics  
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Patients were assessed for clinical eligibility and techinical suitability as per 
chapter 2  methods and materials. 
 
  A radiologist experienced in MRgFUS (WG) analyzed the screening MR images 
to determine patient suitability for the procedure according to set parameters as 
outlined in Figure 1. 
 
In summary, patients were deemed suitable for MRgFUS if they had up to six 
uterine fibroids clearly visible on MRI that were no more than 14 cm away from 
the skin line. Mitigating techniques to overcome issues of an excessive amount of 
bowel in the potential beam path were attempted. These included bladder filling to 
physically raise the uterus and push bowel loops upwards and rectal insertion of 
an inflated Sengstaken tube in an attempt to push the uterus more anteriorly 
displacing bowel loops. In cases where bowel could not be shifted, patients were 
excluded from consideration, as air bubbles or hard particles present in the bowel 
may reflect or absorb the ultrasonic energy. Patients with longitudinal scars in the 
beam path, and transverse scars that could not be seen on the MR images were 
excluded, as scar tissue may absorb the ultrasound energy and cause pain or even 
a skin burn (see figure 2). Overcoming the scar problem is discussed further in 
this thesis.  
Patients with fibroid volumes of more than 500cc, or a hyper-intense fibroid on 
T2 weighted imaging were pre-treated with a GnRH analogue for three months in 
an effort to reduce the size and vascularity of the fibroid (this will be discussed 
further in chapter 4).  
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Chapter 3 Figure 1: Flowchart showing criteria used to assess patient suitabiliy 
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Chapter 3 Figure 2: Full thickness scar burn created by treating directly 
through a previous caesarean section scar. This patient required plastic 
surgery
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MRgFUS procedure  
 
All MRgFUS procedures were performed using the ExAblate 2000 (InSightec, 
Haifa, Israel), which is fully integrated with a 1.5 Tesla MR scanner (GE Medical 
Systems, Milwaukee, WI) as outlined in chapter 2 Methods and Materials. 
 
 
Statistical analysis 
Summary descriptive statistics were used for demographic data, symptom-severity 
scores (SSS) and volume measurements. A paired Students t-test was used for 
comparison of SSS and measured volumes before and after treatment. Null 
hypotheses were rejected at a P level of less than 0.05.  
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Results 
 
Between September 2005 and December 2006, 144 patients attended the Fibroid 
Clinic at St. Mary’s Hospital, in search of minimally invasive treatment for their 
fibroids. Patients were counseled regarding current treatment options, and 100 of 
them requested to have the non-invasive MRgFUS treatment. The remaining 44 
patients opted for either surgical management, UAE or no treatment. The 100 
patients requesting MRgFUS form the initial patient group. Demographics and 
patient characteristics of this group are described in table 1. 
 
All 100 patients requesting MRgFUS were found to be clinically eligible for the 
treatment after a physical examination, according to the exclusion criteria 
specified on page --- chapter 2. These patients were sent for screening MRI scans. 
Of the 100 patients in the initial patient group, 74 patients were assessed as being 
suitable for MRgFUS and 26 patients were deemed not suitable. Of the 26 patients 
not suitable for MRgFUS, seven had bowel completely occluding the acoustic 
window, four had a mixed picture of adenomyosis and fibroids, three had 20 or 
more fibroids of approximately 1cm diameter, one had a dermoid cyst, and 11 had 
scars occluding the treatment window, including four with longitudinal scars. 
Suitability results are summarized in figure 3. 
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Chapter 3 Figure 3: This illustration summarizes suitability results. 
 
Of the suitable patients, one patient had bowel across the acoustic window, 
covering the front of the fibroid. This patient was re-assessed following bladder 
filling and deemed anatomically suitable for MRgFUS. The filled bladder had 
elevated the whole uterus, thereby pushing the bowel clear from the acoustic 
window (see figure 4). 
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Chapter 3 Figure 4: Figure showing bowel clearance from the acoustic 
window by bladder filling. Arrows delineate the position of the bowel.  Left 
image is pre-bladder fill, right is post-bladder fill. 
 
 
 
 
 
 
 
 
 
 
 Bowel 
 Bowel 
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Chapter 3 Figure 5: Figure showing bowel clearance from the acoustic 
window by an inflated sengstaken tube. Arrows delineate the position of 
the bowel.  The top image shows bowel between anterior abdominal wall 
and the uterus which has been displaced in the lower image by the uterus 
which has been pushed anteriorly by the Sengstaken tube. 
Bowel 
Bowel 
Sengstaken tube 
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Sixty-five (88%) of the treated patients were given three monthly injections of a 
GnRH analogue prior to treatment, either to shrink the fibroid (see Figure 7) or to 
improve the response to MRgFUS for fibroids that were hyper-intense on T2 
weighted imaging.   
 
Twenty-eight (38%) patients required two sessions of MRgFUS treatment due to 
the presence of large or multiple fibroids. 
 
 
 
 
 
 
Chapter 3 Figure 6: Comparative images of the same patient pre and post 
GnRHa pre-treatment, showing shrinkage in overall fibroid  
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Treatment outcome 
 
The changes in symptom severity score over a period of six months are outlined in 
the graph below. The average SSS at baseline was 69.4 (SD 14.7, range 22 – 96), 
this dropped to an average of 47.1 (range 11- 51). At six months there was a 
further drop in SSS to an average of 38.3 (SD 16.2 range 9- 42). 95% patients 
experienced significant symptom improvement at 6 months (>10 point drop in 
score, p<0.0001), see figure 8. The average non-perfusion achieved was 41.9% 
(range 35- 90%). Average uterine volume at baseline was 768cc (SD 111.4 range 
535.5cc - 1200cc) at six months the average uterine volume had decreased by 
approximately 35% to 504cc range (298 – 734cc) (p<0.0002). Sixty three patients 
(88%) completed follow up to six months. 
 
 
 
Chapter 3 Figure 7: Graph showing symptom improvement over time. 
 
At six months no patients underwent alternative treatments. Two patients required 
prescriptions of tranexamic acid 3 months post treatment, due to heavy bleeding, 
however both of these patients had experienced symptom improvement with a 
shortening in the duration of menses from 10 and 12 days to 4 and 5. 
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No adverse events were reported post procedure, with most patients tolerating the 
procedure well (see figure 8). 
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Chapter 3 Figure 8: Graph illustrating pain experienced by patients pre, 
during and immediately post treatment. 
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Discussion 
 
With an increasing numbers of patients looking for treatment options that afford 
them the least amount of disruption to their daily routine, the appeal of MRgFUS 
is clear and growing. While MRgFUS provides an effective non-invasive 
treatment option (106) for uterine fibroids, the ability to make the procedure 
broadly available to women who may benefit from it requires the establishment of 
patient selection and suitability criteria that are less restrictive than the guidelines 
developed using older MRgFUS technology.  
 
In a previous study (Arleo, Khilnani et al. 2007) 63% of patients inquiring about 
MRgFUS treatment for symptomatic uterine fibroids were clinically eligible, as 
decided per study exclusion criteria. Of these patients, only 25% were then found 
anatomically eligible following MRI screening. However, these findings were 
limited by the use of guidelines and limitations that were more restrictive than 
those needed for the MRgFUS system used in the current study. 
 
In the retrospective analysis reported here, patients participating in the study had 
100% clinical eligibility and 74% anatomical suitability for MRgFUS. The 
increase in clinical eligibility and anatomical suitability in this study compared 
with previous reports likely results from differences in inclusion-exclusion criteria 
(see Table 2).  
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Clinical factor Prior study St. Mary’s 
Insufficient symptoms 
of fibroids 
SSS <21 
Excluded 
Not relevant 
Age <40 or >60 years  Excluded Not relevant 
Desires pregnancy  Excluded Not relevant 
Menopausal  Excluded Not relevant 
Obesity  >250Ibs excluded >250Ibs 
excluded 
Prior UFE  Excluded Not relevant 
IUD, MR imaging 
incompatibility 
Excluded Excluded 
   
Technical factor Prior study St. Mary’s 
Too much fibroid volume  >900cc excluded Not relevant 
Bowel  Excluded Partly mitigated 
Significant adenomyosis  Excluded Excluded 
Pedunculated fibroids  Excluded  Excluded 
Fibroids too small or no 
fibroids  
Excluded Excluded 
Bright T2 fibroid  Excluded Partly mitigated 
Degenerating, necrotic, 
or infracted fibroids  
Excluded  Excluded 
Arterial-venous 
malformation, calcified 
fibroids, or conglomerate 
of fibroids or septated 
fibroids hard to transmit 
heat across 
Excluded Excluded 
 
Chapter 3 Table 2: Comparison of assessment criteria used in earlier 
studies and the St Mary’s centre. 
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In our hospital, minimal age, menstrual status and minimal symptoms severity 
score were not factors for exclusion. In addition, patients who desire future 
pregnancy also are approved for treatment, as there are case reports showing 
successful live birth post treatment (Gavrilova-Jordan, Rose et al. 2007; Hanstede, 
Tempany et al. 2007). 
 
Additionally, several mitigation techniques used in the 
current study allowed for the treatment of some patients who initially had bowel 
obstructing the beam path, large fibroid volumes, scars, or fibroids that were 
hyper-intense on T2 weighted imaging. For patients with obstructing bowel, 
simple measures such as rectal and bladder filling effectively clear bowel away 
from the acoustic window, allowing for increased treatment capacity. Pre-
treatment of large fibroids with a GnRH analog helps to reduce fibroid volume, 
which may improve MRgFUS outcomes. We previously have reported results of a 
study in which 50 women with fibroids greater than 10cm in diameter were 
treated with a three-month course of a GnRH analog prior to MRgFUS (Smart, 
Hindley et al. 2006). This is discussed further in Chapter 5. Results show that 
83% of patients treated with this regimen described significant improvement in 
their uterine fibroid symptoms at 24 months post-MRgFUS. Similarly, from our 
past experience, of treating hyperintense (hyper-vascular) fibroids, we know that 
these types of fibroids are generally resistant to treatment (see figure11). By pre-
treating hyperintense fibroids with GnRHa we are able to reduce vascularity and 
hence intensity within the fibroid allowing for more efficacious treatment. 
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Chapter 3 Figure 9: Left image shows a hyperintense fibroid as compared 
to normal myometrium. The right image is a planning image prior to 
MRgFUS treatment showing the same fibroid post 6 months of GnRHa 
therapy, now hypo-intense when compared to myometrial tissue and 
smaller. 
 
We also have identified an original method of highlighting transverse scars, which 
has improved our visualization of scar tissue and enabled us to treat patients who 
were previously excluded. With this method, scars are painted with a solution of 
nail varnish and paramagnetic iron oxide particles, providing an obvious artifact 
along the line of the scar, which can easily be avoided by appropriate positioning 
and angling of the ultrasound beam. This will be discussed further on in chapter 4. 
 
The strength of this particular study lies in the number of uterine fibroid patients 
that have been treated with MRgFUS at this institution and long-term experience 
of the staff in selecting patients for the procedure. This experience has enabled the 
identification of a variety of techniques that may be used to expand the pool of 
patients for which MRgFUS may provide a safe and effective treatment for 
uterine fibroids. The treatment outcomes in this group of women are very 
comparative with other published data from sites using more restrictive criteria. In 
2004 Stewart et al published results on 109 women undergoing MRgFUS. 79.3% 
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reported significant improvement in symptoms (>10 point improvement of SSS) 
at six months post treatment (Hindley, Gedroyc et al. 2004). 
  
Guidelines developed from this experience base are expected to provide a greater 
number of women with a non-invasive approach to managing symptomatic uterine 
fibroids, without any compromise in efficacy. 
 
The main weakness of the study is that the statistics do not show the suitability of 
MRgFUS for the general population of women suffering from uterine fibroids 
symptoms but was dependent on patients who were almost self-selected in that 
they specifically requested minimal invasive treatments. Referring gynecologists 
conducted additional assessments prior to referring patients to the Fibroid Clinic, 
and data related to the screening criteria used by individual physicians were not 
available for inclusion here. 
 
In conclusion, we have found that the use of the mitigation techniques described 
above makes it possible to offer MRgFUS to a much larger subset of patients than 
previously believed. Further studies to evaluate these techniques may help to 
refine further the selection and suitability criteria for MRgFUS as a treatment for 
symptomatic uterine fibroids. 
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CHAPTER 4: MRgFUS IN THE TREATMENT OF WOMEN 
WITH UTERINE FIBROIDS AND ABDOMINAL SCARS 
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Summary: 
 
The aim of the study was to identify an effective method of ensuring safe 
MRgFUS treatment of patients with symptomatic uterine fibroids and abdominal 
scars.  
 
 We describe the treatment and outcomes of 25 patients who presented with 
symptomatic uterine fibroids and an abdominal scar. A solution containing 
paramagnetic iron oxide particles was used to highlight the scar during treatment, 
making it visible on MR images obtained during the planning of treatment. 
 
We hypothesised that by being able to identify abdominal scars on MRI we could 
accurately target treatment to avoid the scar region, safely treating women who 
presented with scars. 
 
 All women were treated with no immediate complications. No episodes of skin 
burns, ulceration or skin redness were reported. Quality of life scores were 
compared at baseline, 3 months and 6 months post treatment. The non-perfused 
volume achieved in the targeted fibroid tissue was also calculated for each patient, 
using volumetric analysis, the average ablation created was 65%. 
 
Conclusion: Using Paramagnetic iron oxide solution to highlight transverse 
abdominal scars, allows them to be easily identified on MRI and therefore 
avoidance of the scars can be ensured by the operator, allowing safe but also 
effective treatment of these women, who were previously excluded. 
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Introduction 
 
The safety profile of MRgFUS has been proven in various studies with only mild 
adverse events including, urine infection, temporary nerve irritation and skin 
redness being reported for the majority of patients (Hindley, Gedroyc et al. 2004; 
Smart, Hindley et al. 2006). 
 
A serious adverse event that was reported in our centre at St Mary’s in one of our 
early research patients, of a full – thickness skin burn (see Chapter 3 figure 2) that 
required skin grafting led to the presence of any abdominal scars being a 
contraindication to treatment with MRgFUS. 
Because scar tissue is more fibrotic and less vascular than normal skin tissue, it 
absorbs more ultrasound energy when compared to normal abdominal tissue. In 
addition the scar area can be de-nervated resulting in the danger of over-heating 
the skin without the patient experiencing the sensation of pain as a warning sign. 
Because of this the operator/ treating physician is instructed to avoid the delivery 
of energy through the scar area when treating women with abdominal scars. Due 
to the difficulty in the identification of scars on MRI, this was near impossible to 
ensure and hence our exclusion of these women from treatment (see figure 1). 
 
However due to the presentation of many women with either caesarean section or 
myomectomy scars, we identified an original method of highlighting transverse 
scars, which has improved our visualization of scar tissue and enabled us to treat 
patients who were previously excluded. With this method, scars are painted with a 
solution of nail varnish and paramagnetic iron oxide particles, providing an 
obvious artifact along the line of the scar, which can easily be avoided by 
appropriate positioning and angling of the ultrasound beam. 
 
The aim of this study was to identify the effectiveness of this technique in 
allowing a safe and efficacious MRgFUS treatment. 
 
 
 
 
 
130 
 
 
 
 
Chapter 4 Figure 1: Treatment assessment scan performed prior to 
treatment with full bladder. The scar location not visible on MRI but is 
marked with a cod liver oil tablet (which shows up on scan but cannot be 
used during treatment due to heat bursting the capsule) 
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Chapter 4 Figure 2: A photograph of the same patient, showing an 
abdominal scar from a caesarean section 
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Patients and methods 
 
Twenty five women who presented consecutively to the gynaecology clinic at St 
Mary’s Hospital, London with symptomatic uterine fibroids and an abdominal 
scar were treated with MRgFUS. All women had a screening MRI scan to 
determine technical suitability for MRgFUS treatment as assessed by a consultant 
radiologist. On the day of treatment care was taken to ensure that the pubic area 
was shaved clear of any hair to avoid the risk of air bubbles forming. 
 
Several different solutions were tried and tested prior to achieving a solution 
which created an artefact easily visible on MR scan. The first solution tried was a 
nail varnish said to contain iron particles, the second was a mixture of gadolinium 
(a contrast agent in routine use at our department) and nail varnish to a ratio of 1:1 
the third solution was Endorem (a contrast agent) mixed with nail varnish again to 
a ratio of 1:1 (See figure 3). This proved to be the most effective marker; creating 
the most artefacts. Endorem (Guerbet, Sulzbach) is a super-paramagnetic contrast 
agent for magnetic resonance imaging of the liver and spleen. The contrast agent 
consists of dextran-coated iron oxide particles with a size distribution between 
120 and 180 nm and an iron concentration of 0.2 mol/l. Various different 
concentrations of Endorem to nail varnish solution were tried and tested to obtain 
the superior marker (see figure 4).  Solution 1: consisted of 1 ml Endorem and 
10ml of nail varnish, solution 2: 2ml of Endorem added to 10ml of nail varnish, 
solution 3: 5ml of Endorem to 10 ml of nail varnish. It was discovered that 4 mls 
of Endorem added to a 10ml bottle of nail varnish provided the best marking, in 
that a sufficient artefact was created on MRI whilst maintaining the consistency of 
the solution to allow easy coverage of the scar. The area of the scar was painted 
across its entirety with the iron oxide solution. All women were consented for the 
risk of skin burn and advised to inform the physician and nurse of any skin 
warming sensation experienced at any time throughout the procedure. 
Identification of the position of the scar was made on the MR images collated and 
the position was marked identifying it as a low energy density region (LEDR). 
Angulations of the beam as necessary to avoid the area were made.  During the 
procedure the occurrence of any skin pain and frequency was noted. At the end of 
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the procedure, any redness, ulceration or changes to skin was also noted. 
Immediate treatment outcome was assessed by the non-perfused volume (NPV) 
achieved. All patients filled in the UFS-QOL prior and at 3 and 6 months post 
procedure. 
 
 
Statistical analysis 
Summary descriptive statistics were used for demographic data, QOL scores and 
volume measurements. Students t- test was used for comparison of SSS before 
and after treatment. Null hypotheses were rejected at a P level of less than 0.05.  
 
 
 
Chapter 2 Figure 3: Photograph showing different markers being tested 
on a volunteer’s lower limb. The 1st marker identified by 1 cod liver oil 
tablet was nail varnish only. The 2nd is gadolinium, the 3rd
 
 Endorem. 
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Chapter 2 Figure 4: Various different concentrations were tried to identify 
the correct balance of contrast agent to nail varnish. It was identified that a 
concentration of 4mls of Endorem in a 10 ml bottle of nail varnish was the 
superior marker. 
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Results: 
 
A total of 25 women underwent MRgFUS. The mean age of the women was 37 
years (+/- 8; range 29-45). No subjects were post-menopausal. The mean body 
mass index (BMI) was measured as 24.87 (+/- 4.13; range 19-38) and the ethnic 
origin of the group was as follows; 17 Caucasian, 5 Black (African or Afro-
Caribbean) and 3 Asian origin. Demographics and patient characteristics of this 
group are described in table 1 below.  
Six patients presented with multiple fibroids and nineteen patients with a single 
fibroid. The average fibroid volume targeted was 740cc (range 48cc-840cc). 
The primary presenting symptom was menorrhagia in 23 (92%) patients, with 2 
(8%) patients presenting with pressure symptoms in the form of urinary 
frequency. 
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Chapter 4 Table 1: Patient Demographics  
N=25 
 
Age (years)  
 Mean (Years) 37 
Range (Years) 29-52 
BMI (kg/m2
 
)  
 Mean 24.9 
Range 19 – 38 
Hormonal Status  
 
 Pre-menopausal 100% 
Peri-menopausal 0% 
Race 
 White 68% 
Asian 12% 
African 20% 
Number of fibroids 
 Patients with a single fibroid 76% 
Patients with multiple fibroid 24% 
 
 
Clinical follow-up 
No incidences of skin pain were reported during treatment. Examination of the 
skin post treatment revealed no incidences of skin redness or any skin changes. 
The non-perfused volume (NPV) created in the targeted treatment region was 
calculated as a percentage of the total fibroid. The average NPV achieved was 
65% (range 35-80%) which compared favourably with results from other studies. 
All women reached the 6 month follow up stage. The average baseline quality of 
life (QOL) score was 54.5 (range 34-91) at 3 months this was 41.2 (range 9-63) 
and at by 6 months the average QOL score had dropped by 64% to 34.7 (range 5-
64, p<0.0001). 
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Discussion: 
 
Following the first report of a full thickness burn in a woman following MRgFUS 
treatment (Leon-Villapalos, Kaniorou-Larai et al. 2005), despite continuous real-
time MR imaging and thermal mapping, patients with abdominal scars have been 
excluded from treatment with MRgFUS. It was later understood that scar tissue is 
more fibrotic and less vascular which causes it to absorb more energy compared 
to normal abdominal tissue. Also as the scar area is to some extent de-nervated it 
results in a danger of over-heating the skin without the patient experiencing any 
sensation of pain as a warning sign. Scar identification on MR is difficult and 
therefore avoidance of the scar has been problematic. 
 
Due to the recurrent nature of uterine fibroids however, this has posed a treatment 
dilemma for patients who seek a non-invasive treatment option following a 
previous myomectomy or other abdominal surgery. By direct visual observation 
of the scar, it was anticipated that complete avoidance of the scar could be 
achieved by various techniques, including bladder filling to lift the uterus above 
the scar creating a clear acoustic window (see figure 5).  
 
Angulation of the beam could also achieve a clear beam pathway without going 
through the scar (see figure 6). By painting the scar completely with a 
paramagnetic iron oxide solution we have achieved a method by which an 
abdominal wall scar may easily be identified and avoided on MR imaging without 
affecting treatment outcome. All twenty five patients completed treatment without 
any adverse effects. One patient had a NPV of <40% due to the hyper-intensity of 
her fibroid causing poor thermal necrosis. This method of highlighting the scar 
provides the operator with complete control on the safety of treatment, without 
having to rely on the patient to relay sensations of skin pain. This method has 
allowed us to extend this non-invasive treatment to a significant subset of patients 
who previously had been excluded.  
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Chapter 4 Figure 5: Image showing abdominal scar easily visible on MR 
imaging, by filling the bladder the scar can be avoided completely. 
 
                     
 
 Chapter 4 Figure 6: Image showing angulation of beam to avoid the scar 
(red arrow). 
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CHAPTER 5: MRgFUS FOR THE TREATMENT OF LARGE 
UTERINE FIBROIDS. 
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Summary 
 
The objective of this study was to assess the feasibility and effectiveness of 
treating large uterine fibroids with MRgFUS following pre-treatment with GnRH 
agonists.  
The hypothesis of this study was that by pre treating larger uterine fibroids with 
GnRH agonists, this would allow sufficient shrinkage of larger uterine fibroids, 
which could be maintained following treatment with MRgFUS.  
 
This is a prospective study of women with fibroids in excess of 10cm in diameter 
who received Gonadotrophin Releasing Hormone (GnRH) agonist before 
MRgFUS treatment. Patients were recruited from the Gynaecology outpatient 
clinics and assessed for eligibility. Entry criteria were a set minimum fibroid 
symptom severity score (SSS) of 18 and confirmation of fibroid dimension >10cm 
based on screening MRI. All patients had a 3-month course of GnRH agonists 
followed by MRgFUS treatment. The primary outcome measurement was 
reported change in SSS as judged by the Uterine Fibroid Symptoms and Quality 
of Life Questionnaire (UFS-QOL).  
Comparison was made at enrolment, treatment, 3, 6, 12 and 24 months post-
treatment. Results: Fifty women were enrolled in the study. There was a 50% 
reduction in mean SSS at 6 months and this was maintained for 24 months post 
treatment. There was an average reduction in target fibroid volume of 21% overall 
at 6 months (p<0.01), 37% at 12 months and 34% at 24 months. No serious 
infective complications or emergency operative interventions were recorded. 
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Introduction: 
 
Uterine Leiomyomas have both Oestrogen and Progesterone receptors and as such 
their growth and maintenance are sensitive to oestrogen and / or progesterone, 
with their effects being mediated by local peptide factors (Murphy, Kettel et al. 
1993). 
The depletion of these hormones during the menopause induces a significant 
regression of leiomyomas. A pseudo-menopause status can be created by 
treatment with gonadotrophin releasing hormone analogue treatment (GnRHa) 
treatment (Filicori, Hall et al. 1983). 
 
GnRH is released from the hypothalamus and binds to specific receptors on 
pituitary gonadotrophs, resulting in stimulation of gonadotrophin biosynthesis 
which leads to subsequent modulation of ovarian activities. 
 
GnRH agonist decreases oestrogen and progesterone secretion from the ovary and 
has been used in the treatment of some sex hormone- dependent cancers, 
including breast, prostatic, pancreatic, endometrial and ovarian cancers. Therapy 
of leiomyomas with GnRH agonist has been tried and has been shown to reduce 
leiomyoma volume (Adamson 1992; Watanabe, Nakamura et al. 1992). The 
reduction of tumour volume is associated with a decrease in cell proliferation and 
with an increase in cell loss by apoptosis. The molecular mechanisms involved 
however have not been fully clarified. 
 
GnRH analogue administered once a month can result in approximately a 30 -50% 
(Adamson 1992) reduction in uterine volume and often an associated 
improvement in fibroid-related symptoms due to the accompanying amenorrhea. 
GnRHa treatment is limited for short term use due to unacceptable symptoms such 
as hot flushes and demineralization of bone with prolonged treatment. It is well 
known that on stopping GnRH treatment, there is often a rebound in size and a 
return of symptoms (Friedman, Hoffman et al. 1991). Thus to date GnRHa has 
been advocated as an adjuvant to surgery, both to reduce fibroid volume and to 
control bleeding. 
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The use of MRgFUS is limited in larger fibroids due to the treatment being 
volume dependent. By shrinking the overall uterine volume prior to treatment, we 
can make treatment of these larger fibroids more feasible.   
 
The main hypothesis to be answered by this study is whether ablation of uterine 
fibroids with MRgFUS following three months of treatment with GnRHa therapy, 
will prevent the rebound in both volume and symptoms from the fibroid that is 
seen following treatment with GnRHa alone?  
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Patients and methods 
 
Women with symptomatic uterine fibroids who presented to the Gynaecology 
clinics at St Mary’s Hospital, London, between April 2003 and October 2004 
were recruited and followed up for 12 months by a previous gynaecology research 
fellow, O. Smart. Twenty-four month follow- up and statistics were performed by 
S. Zaher.  All patients were informed about the benefits and potential risks and 
provided written informed consent to participate. Patient’s symptoms were 
assessed using a validated fibroid specific quality of life questionnaire, UFS-QOL 
(Spies, Coyne et al. 2002) and only women meeting the minimum symptom 
severity screening score of 21 points were included. Clinical entry criteria for this 
study dictated a minimum age of 18 years with no desire for future fertility. 
Women with a haematocrit < 25%, a positive pregnancy test, major medical 
disease or contraindication to MRI scanning were excluded from the study. (For 
full inclusion and exclusion criteria please see appendix). 
Pre-treatment Imaging 
All study participants underwent initial MR imaging of the pelvis in a 0.5T 
scanner (GE Medical Systems, Milwaukee, Wis) as detailed in Chapter 2: 
Materials and Methods. Only patients with largest diameter of the target fibroid 
being a minimum of 10cm were included. 
Treatment preparation 
 GnRH agonist, Goserelin 3.6mg (Zoladex, AstraZeneca, UK), was administered 
as a course of 3 subcutaneous injections. The first injection was given on day one 
or two of the menstrual cycle with subsequent injections given twenty eight days 
later. MRgFUS was carried out two–three weeks following the last injection. On 
the day of treatment all patients were requested to shave their abdomen from the 
level of the umbilicus to the pubic symphysis, as experience from sister sites had 
identified the potential of air bubbles being trapped in the pubic hair with resultant 
skin burns. An intravenous cannula for IV analgesia and sedation and urinary 
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catheter were inserted. A pregnancy test was also performed, a positive pregnancy 
test being an exclusion criterion. 
The MRgFUS procedure was performed as outlined previously in this thesis by O. 
Smart. 
 
Statistical analysis 
Summary descriptive statistics were used for demographic data, QOL scores and 
volume measurements. Wilcoxon Rank tests were used for comparison of SSS 
and measured volumes before and after treatment. Null hypotheses were rejected 
at a P level of less than 0.05.  
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Results: 
 
Of the 50 women enrolled in the study, only one was unable to tolerate the 
procedure due to severe claustrophobia and did not undergo magnetic-resonance-
guided focused ultrasound and was included in the screening failure group. The 
mean age of the participating women was 41 years (range 33-52 years). No 
subjects were postmenopausal, and only one was peri-menopausal. The mean 
body mass index was 24.87 (range 19-38), and the ethnic origin of the group was 
as follows: 24 white, 16 black (African or Afro-Caribbean), 3 Asian and 7 ‘other’ 
ethnic origin. 7 women had low transverse abdominal scars, of these, 3 were due 
to previous open myomectomy, 3 following Caesarean section and 1 as a result of 
ovarian cystectomy. One woman had been diagnosed with mild endometriosis but 
the remaining subjects had no history of additional gynaecological pathology.  
Treatment outcomes 
Thirty-eight of the 49 women completed MRgFUS treatment in one session and 
11 subjects required a second visit to complete therapy. Mean treatment time was 
183 mins (+/- 24; range 150-240) for the first treatment and 178 mins (+/-27; 
range 135-210) for the second session with an average of 50 (+/- 20) sonications 
being delivered per patient. Total analgesic requirement during the procedure 
averaged 70 mg of Pethidine (range 0-100) and 7 mg of Diazepam (Range 0-10). 
All patients remained fully conscious and communicative throughout treatment. 
The subjective assessment of change in symptoms for each patient, based on the 
UFS-QOL, is shown in figure 1. At enrolment mean symptom severity score was 
61.82. On the day of treatment this had decreased by almost two-thirds (SSS = 
22.44), which is explained by the amenorrhoea and reduced fibroid volume 
induced by 3 months of pre-treatment with GnRH agonist. Despite a small rise in 
symptom score, as would be expected following the return of menses, the mean 
SSS at 6, 12 and 24 months remained 50% lower than at enrolment (SSS =30.31).  
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Chapter 5 Figure 1: Shows the mean changes in QOL scores up to 24 
months post treatment. This graph shows a substantial initial fall as 
described above followed by a continued symptom score reduction post 
FUS treatment and post cessation of GNRH treatment indicating 
prolonged improvement over this time course.  
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The mean uterine volume at baseline was 1217 cm3 (+/-601). Following treatment 
with 3 doses of GnRH agonists there was an average volume reduction by 38.5 % 
to 724 cm3
There was a significant reduction in volume of the target fibroid of 21% at 6 
months and 37% at 12 months over the duration of the study (mean = 105 cm
 (+/-369). Following treatment with MRgFUS patients were scanned at 
an average interval of 6 months and 5 days (+/- 12 days). No evidence of oedema 
or soft tissue damage outside of the target fibroid was seen on follow up MR 
imaging. Contrast enhanced T1 weighted images demonstrated a mean non-
perfused volume of 144 cm3 (+/- 127) created within the target fibroid. 
3; 
p<0.01). By 24 months mean uterine volume was 419.04 cm3 (p<0.001 range 69-
1525 cm3
Adverse Events 
). Figure 2 compares volume reduction at baseline and 24 months post-
procedure. 
Adverse events were monitored and reviewed at each study visit (treatment, 1 
week, 3 months, and 6, 12 and 24 months). Two patients described lower back 
pain immediately after treatment, which persisted beyond 1 week but had resolved 
by 6 months. Small superficial skin burns (< 2cm diameter) occurred in 2 patients 
and healed with minimal scarring. The only serious adverse event was a 5cm full 
thickness skin burn in a patient with a previous low transverse laparotomy scar 
mentioned earlier in this work. This event was pre-scar marking and prompted our 
investigation into overcoming this problem. This patient did not report any pain 
during the procedure due to a region of localised anaesthesia adjacent to the scar. 
Excision and direct closure of the area was carried out with a good cosmetic result 
at 6 months. Other adverse events documented were fainting during treatment 
(n=1), urticarial reaction to IV pethidine (n=1) and a report of sensory loss to a 
small area of skin in the right groin, which persisted beyond 6 months (n=1).  
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Alternative treatments 
11 patients had alternative treatments, these included Myomectomy (n=2) 
Hysterctomy (n=4) Uterine Artery Embolisation (n=3) and percutaneous laser 
ablation (n=2). 3 of these were after 6 months post-treatment, 8 of the alternative 
treatments took place after 12 months post-treatment. 
In total 26 patients completed 24 month follow-up, 9 did not consent to the 
longer-term follow up, 11 patients had alternative treatments and 3 were lost to 
follow up. 
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Discussion: 
 
The management of uterine fibroids has undergone a revolution in the past few 
decades with better understanding of its impact on fertility and technical advances 
in endoscopy and radiologic embolisation techniques and also pharmaceutical 
alternatives such as gonadotrophin-releasing hormone agonist and progesterone 
intrauterine contraceptive devices. Much work is still needed to understand better 
molecular mechanisms and cellular biology before the arrest of tumour genesis 
can be achieved. We attempted to achieve a similar clinical effect by arresting 
fibroid growth by thermo-ablation of a hormonally pre-treated fibroid (see figure 
3 and 4).  
 
 
Chapter 5 Figure 3: Study patient 5. Left image shows a Sagittal view of a 
10cm fibroid prior to treatment. Image on the right shows the same fibroid 
following 3 months treatment with GnRHa injections. 
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Chapter 5 Figure 4: Post treatment images of study patient 5. Left image 
shows a contrast enhanced image of the same fibroid immediately post 
treatment with MRgFUS. The image on the right shows the same fibroid 
12 months post treatment, significantly smaller than at baseline. 
 
The use of GnRH agonist pre-treatment is well established and routinely used by 
many surgeons prior to open or endoscopic surgery for uterine fibroids. This 
regulatory neuropeptide, when administered in a continuous fashion, creates a 
temporary menopausal state. It has been observed that in this hormonal milieu a 
significant reduction in fibroid volume occurs. Since fibroids rapidly re-grow to 
their original size within a few months of discontinuing GnRH agonists 
(Friedman, Hoffman et al. 1991), (see control case of ultrasound images figures 5-
7 below) and longer-term administration is associated with significant morbidity, 
such as osteopenia, this type of drug cannot be used as a definite treatment for 
symptomatic fibroids.  
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However, as a time limited adjunctive therapy, it provides the technical 
advantages of smaller tumour size and also the additional benefit of reduction in 
vascular flow.  
 
 
  
Chapter 5 Figure 5: Ultrasound image of control patient prior to GnRHa 
treatment. Size of fibroid pre-treatment measures 9.04cm 
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Chapter 5 Figure 6: Ultrasound image of control patient after 6 
months of GnRHa therapy. Fibroid now measures 5.69 cm. 
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Chapter 5 Figure 7: Ultrasound image of control patient 1 year post 
cessation of GnRHa treatment. There has been a rebound in fibroid 
size to 9.91 cm. 
 
When MRgFUS is performed large areas of coagulative necrosis can be achieved, 
in the shrunken fibroid, resulting in a prolongation of the symptomatic 
improvement seen in patients. This has allowed the technique of MRgFUS to be 
offered to women with larger fibroids. The time intensive nature of the procedure 
has meant that treatment of these women had previously been particularly lengthy 
and unsuccessful, with minimal shrinkage or non-perfusion achieved. (See figures 
8-9). 
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Chapter 5 Figure 8: A Sagittal MR image of a giant fibroid uterus 
extending well above the umbilicus measuring 19.5 cm. 
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Chapter 5 Figure 9: A contrast enhanced image of the same patient 
in figure 8 post treatment with MRgFUS. The darkened central area 
corresponds to the ablation created within the fibroid. A massive 
volume of perfused fibroid tissue remains, indicating the complexity 
in treating large fibroids without pre-treatment with GnRHa 
injections. 
 
We identified that by ablating the fibroid in patients pre-treated with a course of 
GnRH analogues, we can achieve long-term symptomatic improvement in patients 
of 24 months and beyond. We are also able to maintain the initial shrinkage that is 
often seen with GnRH analogues. 
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The main limitation of this study was that this study was initially planned with a 
12 month follow up, as such not all of our recruited patients agreed to persist with 
follow up beyond the 12 month stage. Further work is under way to obtain longer 
term follow up results in our treated patients, unpublished data are optimistic, with 
some patients showing continued symptomatic relief beyond 36 months post-
treatment. 
 
In conclusion, we describe a non-invasive method which can be used to prolong 
the symptomatic relief afforded to patients following GnRHa administration, 
without actually having to continue administration of injections and hence any of 
the hormonal side-effects. 
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CHAPTER 6: MRgFUS FOR THE TREATMENT OF UTERINE 
FIBROIDS IN WOMEN DESIRING FUTURE PREGNANCIES. 
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Summary 
 
The main aims of this study were to evaluate the safety of MRgFUS in the 
treatment of uterine fibroids in women desiring future fertility. Safety was 
determined by the evaluation of the incidence and severity of procedure related 
complications, including pregnancy, delivery and post-partum complications. This 
was a multicentre, international study (for participating sites please see appendix), 
pre-menopausal women who presented to the outpatient gynaecology clinic with 
symptomatic uterine fibroids and a desire to become pregnant within the next 12 
months were recruited.  
 
One hundred and sixteen women were recruited from five centres. There were 
sixty four reported pregnancies in sixty one women, with 30 completed deliveries. 
The mean time to conception was 8 months after treatment (range 4-11 months).  
The spontaneous abortion rate was 27%, with an elective pregnancy termination 
rate of 11%. The mean birth weight was 3.3kg, and the vaginal delivery rate was 
64%. There were no reported cases of uterine rupture, premature labour, abnormal 
placentation or placental abruption. The preliminary fertility data are promising; 
with women treated with MRgFUS for their symptomatic fibroids being able to 
spontaneously conceive, carry and deliver safely.  
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Introduction 
Uterine fibroids are the most common neoplasm of the female pelvis, increasing 
in incidence in the later reproductive years. A shift in cultural trends of women 
delaying pregnancy has resulted in many women presenting with symptomatic 
fibroids at a stage when preservation of the uterus is a priority. The national office 
of statistics reports a 74% increase in the number of conceptions in the 40-44 age 
group in 2004, when compared to 1988. This has resulted in a dilemma for the 
gynaecologist who is faced with providing an effective solution to his patient’s 
fibroid symptoms, whilst ensuring no detriment to her fertility. The current 
standard of practice remains surgical in the many forms of myomectomy 
(laparotomy, laparoscopy, hysteroscopy). 
Despite myomectomy being the gold standard, few studies agree on the actual 
increase in pregnancy rates following surgery, this being described as anything 
from 44-81% however all report a fall in rate of pregnancy loss (Marchionni, 
Fambrini et al. 2004; Sinclair, Gaither et al. 2005; Seracchioli, Manuzzi et al. 
2006). 
Unfortunately fertility enhancement is not the only factor to be considered when 
recommending treatment but also the complications related to their removal. 
During myomectomy part of the uterine wall is severed in order to enucleate the 
fibroid. This damage to the wall is independent of the surgical technique used. 
Surgical sutures are placed in order to control bleeding and close the severed 
uterine wall, an ensuing fibrotic scar forms. In addition to the resulting relative 
weakness of the uterine wall post-surgery; which may result in the low but major 
risk of uterine rupture during pregnancy/labour; adhesion formation within the 
abdomen can also form resulting in mechanical infertility.  
A further point to be considered is the risk of surgery-associated complications. 
Even if uncommon, intra-operative complications such as; bladder, bowel, 
ureteral injury, severe bleeding and unintended conversion to hysterectomy have 
been reported. Moreover, postoperative complications such as fistula or 
thrombosis and embolism may also occur (Altgassen, Kuss et al. 2006). The 
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minimal invasive treatment option of UAE has increased in popularity and 
reported pregnancies following treatment are plentiful. Although most 
pregnancies following UAE have good outcomes, the risk of preterm delivery, 
spontaneous abortion, abnormal placentation and postpartum haemorrhage, are 
increased following uterine artery embolisation compared to myomectomy. This 
may be due to the resultant ischaemia which not only occurs in the fibroid but the 
entire uterus. This ischaemia may result in chronic weakness of the pregnant 
uterus. Uterine rupture has been reported with both myomectomy and UAE 
(Lieng, Istre et al. 2004) (Vidal, Michel et al. 2008). 
Although both myomectomy and UAE are seen as effective and safe treatment 
options for fibroids, the increase in pregnancy complications seen with UAE 
means that patients should be recommended myomectomy as the treatment of 
choice over UAE in those desiring future fertility. 
With MRgFUS heat ablation is limited to the core of the fibroid and no damage to 
the surrounding uterine wall occurs. Real time monitoring of the volume of 
ablation enables limitation of the thermal damage to a distinct targeted region of 
the fibroid as shown in pathology specimens (Jolesz 2009) and MR contrast 
imaging. Accordingly there arises the hypothesis that MRgFUS may enable non-
invasive treatment of uterine fibroids in women desiring pregnancy, without 
compromise to the integrity of the uterus or increase in pregnancy related risks. 
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Patients and methods 
As described previously this was a multi-centre study. For the rest of this chapter 
we will describe the recruitment procedure, patient population and results of our 
centre’s involvement.  
Pre-menopausal women presenting to the gynaecology clinic at St Mary’s 
Hospital between Aug 2005 and Aug 2006, who were seeking treatment for 
uterine leiomyomas and a desire to retain fertility were recruited into the study. A 
definitive diagnosis of a uterine fibroid(s) was confirmed both by clinical 
examination and MR imaging prior to enrolment.  All MR images were reported 
by a consultant radiologist who evaluated size and location of uterine fibroids and 
overall pelvic anatomy. Patients were required to express a desire for pregnancy in 
the next 12 months post treatment. Clinical entry criteria for this study dictated a 
minimum age of 20 and a maximum of 40, for those planning to have egg 
donation the maximum age was 46. All women over the age of 38 required to be 
tested for normal ovarian function as judged by endocrinological evaluation. 
Patients with an abnormal cervical smear or any other gynaecological abnormality 
were excluded from the study. Couples who had failed to conceive one year after 
trying were asked to undergo tests for normal ovarian function and tubal patency, 
partners were asked to provide a semen analysis.  
An absolute contraindication to treatment was the finding of loops of bowel or 
abdominal wall scars in the projected ultrasound beam pathway. All patients were 
informed about the benefits and potential risks and provided written informed 
consent to participate.   
Study design 
This was a prospective, phase II, non-randomised, multicentre study to evaluate 
the safety of MRgFUS in the treatment of uterine fibroids in women desiring 
future fertility. All patients were treated with MRgFUS and then followed 
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clinically for 12 months and/ or through future pregnancy to evaluate the change 
in their symptoms and the course of their pregnancies. 
 
Treatment procedure: 
Patients were screened for eligibility to the study. Those meeting the criteria were 
offered an informed consent to sign.  
The MRgFUS procedure was performed as outlined in Chapter 2: Materials and 
Methods.  
Follow-up  
Follow-up visits were scheduled at 1 week, 3 months, 6 months and a final visit 
conducted either at 12 months, if the patient did not fall pregnant or 3 months 
after delivery or miscarriage, if she did. Patients were assessed for overall health 
related quality of life using the UFS-QOL, physical wellbeing, as well as 
device/procedure related adverse events that may have occurred during the 
follow-up period. 
Patients were instructed not to conceive before three months after the last 
treatment procedure. All study participants were instructed to report their 
pregnancy as soon as possible. All patients who fell pregnant were followed up as 
per their local hospital’s policy of care for high risk pregnancies. An explanatory 
letter outlining the procedure was given to the patient and her obstetrician.  Mode 
of delivery was determined by the treating obstetrician.  
Statistical analysis 
Summary descriptive statistics were used for demographic data, QOL scores and 
volume measurements. Student t-tests were used for comparison of SSS before 
and after treatment. Null hypotheses were rejected at a P level of less than 0.05.  
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Results 
Study Population 
Thirty two women enrolled in the study at our centre, the mean age was 38 years 
(+/- 4.6; range 23-46). All subjects were pre-menopausal. The mean BMI was 
measured as 24.87 (+/- 4.13; range 19-38) and the ethnic origin of the group was 
as follows; 7 Caucasian, 24 Black (African or Afro-Caribbean) and 1 other ethnic 
origin. 
 
All women were keen to conceive, twenty four women were nulliparous, with 5 of 
these having previous miscarriages. Seven women were parous and one had 4 
previous failed IVF treatments. No subjects had any history of additional 
gynaecological pathology. 
Treatment outcomes 
Twenty eight of the thirty-two women completed MRgFUS treatment in one 
session and 4 subjects required a second visit to complete therapy. Mean 
treatment time was 173 mins (+/- 30; range 143-203) for the first treatment and 
145 mins (+/-27; range 118-172) for the second session with an average of 64 (+/- 
20) sonications being delivered per patient. Total analgesic requirement during the 
procedure averaged 65 mg of Pethidine (range 0-100) and 8 mg of Diazepam 
(Range 0-10). All patients remained fully conscious and communicative 
throughout treatment. 
Figure 1 below summarises pain experienced by patients at various time points 
during MRgFUS. They were asked to score pain on a scale between 0 and 4, 
where a score of 0 indicates no pain and a score of 4 indicates severe pain. This 
was recorded before, during and immediately after treatment. Of note is the 
finding that although the majority of patients described moderate pain during 
treatment, this had disappeared, in all but one case, by the time the patient reached 
the recovery area. 
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Chapter 6 Figure 1: Pain Experienced during treatment. 
 
Clinical Follow up 
Twenty nine women completed follow up to 12 months with no pregnancy. One 
woman became pregnant 5 months post treatment and miscarried at 12 weeks. 
One lady conceived 10 months post treatment delivering a healthy female infant at 
term and another underwent a successful IVF treatment with egg donation 
delivering at term a healthy male infant. These cases will be described in detail 
later. The results of the objective assessment of change in symptoms, based on the 
UFS-QOL, are shown below in figure 2. At enrolment mean symptom severity 
score was 66.4, this had almost halved at 3 months to 37.3, the mean SSS at 6 and 
12 months was still 50% lower than at enrolment (SSS =30.31 and 28.2 
respectively, p<0.002).  
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 Chapter 6 Figure 2: This graph shows a substantial initial fall as described 
above followed by a continued symptom score reduction post FUS 
treatment, indicating prolonged improvement over this time course.  
Adverse Events 
Adverse events were monitored and reviewed at each study visit (treatment, 1 
week, 3 months, and 6 and 12 months). Three patients described lower back pain 
immediately after treatment, which did not persist beyond 1 week. One woman 
developed a urine infection assumed to be catheter related and was placed on 
antibiotics. There were no other adverse events. 
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Uncomplicated Term Vaginal delivery following Magnetic Resonance 
guided Focused Ultrasound Surgery for Uterine Fibroids. 
 
The objective of this case study was to describe an uncomplicated term vaginal 
delivery after MRgFUS for symptomatic uterine fibroids. 
 
 
 
Case: 
A 35 year old para 1+0, presented to the fibroid clinic at our hospital with a 
known diagnosis of fibroids made 3 years ago. The patient’s first pregnancy 
resulted in a premature delivery at 28 weeks (attributed to fibroids) of a 1.17kg 
female infant. She presented to our unit with a history of fibroid related 
menorraghia and urinary pressure symptoms including frequency and nocturia.  
Symptoms were assessed using the uterine fibroid specific quality of life 
Questionnaire (UFS-QOL) (Spies, Coyne et al. 2002). The patient’s baseline score 
was 65. Severity of symptoms is directly related to the greatness of the score with 
a maximum score being 100.  
In July 2006 radiological MRI assessment deemed she was suitable for treatment 
with MRgFUS. She enrolled in an ongoing clinical trial of MRgFUS for treatment 
of symptomatic fibroids, in women wishing to preserve their fertility. She gave 
informed consent pertaining to risk of skin burns, nerve irritation, unknown 
effects on pregnancy and fulfilled all eligibility criteria for the study. 
 
The patient’s screening MRI (see figure 3) revealed an enlarged fibroid uterus 
with an inferio-superior diameter of 13.5 cm and a uterine volume of 646.5 cm3. 
Five fibroids were identified, the largest being a fundal posterior intra-mural 
fibroid of 5cm, three other anterior intramural fibroids, and a low anterior wall 
fibroid of 4.5 cm which distorted the endometrial cavity posteriorly. 
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Chapter 6 Figure 3: T2 weighted sagittal image of study patient 31 prior to 
treatment 
 
 
The patient had a pre-treatment course of 3 GnRH analogue (triptorelin 3.75mg) 
s/c injections, of which the first was given on the first day of the cycle and 
subsequent injections 28 days after the previous. She then underwent MRgFUS 
treatment in October 2006. Treatment time took 3 hours, the patient complained 
of abdominal cramps during treatment, which resolved at the end of the treatment 
episode. No adverse events occurred and the patient was discharged home with no 
complications. Immediate post-treatment contrast enhanced images revealed 
excellent results with approximately 90% non-perfusion of total fibroid volume 
achieved as calculated by volumetric analysis. 
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By 6 months post the procedure the patient had experienced almost complete 
resolution of her pre-treatment symptoms, with her UFS-QOL score now 24. The 
patient conceived 4 months later, with no antenatal problems noted at booking. 
All booking observations were normal. An anomaly scan performed at 20 weeks 
gestation revealed no abnormalities. Serial sonography at 28, 32, 36 and 40 weeks 
demonstrated appropriate fetal growth with cephalic presentation and an anterior 
placenta, which was not low-lying.          
 
At 41 +6 weeks the patient was admitted for induction of labour as she was past 
her due date. Labour was augmented by artificial rupture of the membranes and 
lasted for 5 hours 8 minutes. Fetal monitoring throughout was reassuring, and an 
uncomplicated vaginal delivery of a healthy female infant with a birth weight of 
3580gms was achieved. Apgar scores were 8 at 1 minute, 9 at 5 minutes and 9 at 
10 minutes. In the institution at which the patient delivered, cord gases are not 
routinely done for non-distressed infants. No paediatrician was required at 
delivery. 
 
6 months post delivery, the patient continues to have maintained symptomatic 
improvement, with a QOL score of 22. Contrast –enhanced MRI shows persistent 
non-perfusion of all fibroids, in addition there has been shrinkage in the overall 
uterine volume to 376.3 cm3
 
 (See figure 4). 
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Chapter 6 Figure 4: Contrast enhanced image of the same patient 
(number 31) showing non-perfusion of all fibroids, and overall reduction in 
uterine volume. 
 
In conclusion we describe the first U.K pregnancy and successful delivery in a 
woman who was part of a fertility trial and specifically treated with MRgFUS for 
symptomatic fibroids that had caused a previous premature delivery at 28 weeks. 
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IVF following Magnetic Resonance guided Focused Ultrasound 
Surgery for uterine fibroids 
 
The objective of this case study was to describe an IVF pregnancy and delivery 
after MRgFUS for symptomatic uterine fibroids. 
Fibroids and in particular sub-mucosal fibroids are thought to reduce the 
implantation rates following IVF. A review of IVF outcomes in 24 women found 
a 70% decrease in pregnancy rate attributable to a 72 % decrease in implantation 
rate in women with sub-mucosal fibroids, when compared to infertile controls 
(129). 
 
This study has led to the recommendation by most reproductive specialists 
for the resection of sub-mucosal fibroids before proceeding with assisted 
reproductive technologies. The non-invasive nature of ExAblate whereby only the 
uterine fibroids undergo thermal ablation with no damage to healthy surrounding 
tissue suggests that MRgFUS should be a safe approach for women who want to 
preserve their fertility and perhaps may provide a non-invasive treatment 
alternative for this sub-set of women. 
We describe the first IVF pregnancy following MRgFUS treatment for 
symptomatic uterine fibroids. 
 
Case: 
A 45 year old para 0+1, presented to the fibroid clinic at our hospital with a 
known diagnosis of fibroids. The patient had 4 previous IVF cycles, three from 
egg donations and 1 with her own egg. She had one pregnancy resulting in a first 
trimester miscarriage 2 years ago. She presented to our unit with a history of 
fibroid related menorraghia and a desire to preserve her fertility. 
Symptoms were assessed using the uterine fibroid specific quality of life 
Questionnaire (UFS-QOL) (108). The patient’s baseline score was 72. Severity of 
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symptoms is directly related to the greatness of the score with a maximum score 
being 100.  
 
In January 2007 radiological MRI assessment deemed she was suitable for 
treatment with MRgFUS, with an effective acoustic window to the fibroid.  
The patient’s screening MRI revealed an enlarged fibroid uterus with an inferio-
superior diameter of 9.4 cm due to a single anterior wall partially sub-mucosal 
fibroid measuring 9 x 6.2 x 7.1 cm, which had resulted in distortion of the 
endometrial cavity (See figure 5). 
 
 
 
 
Chapter 6 Figure 5: pre-screening MRI of study patient 13 with a Sagittal 
view of the pelvis, showing an enlarged fibroid uterus with an anterior wall 
fibroid. 
 
Endometrial cavity 
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The patient was counselled on the unknown effects on pregnancy and underwent 
treatment in April 2007. Treatment time took 3 hours, the patient complained of 
abdominal cramps during treatment, which resolved at the end of the treatment 
episode. No adverse events occurred and the patient was discharged home with no 
complications. Immediate post-treatment contrast enhanced images revealed 
excellent results with approximately 90% non-perfusion of total fibroid volume 
achieved as calculated by volumetric analysis. The patient was advised not to 
conceive until 3 months after the procedure. She returned at 3 months for follow-
up imaging and assessment of symptoms. Her 3 month follow up scan revealed 
significant shrinkage in the fibroid volume which now measured 5.1 x 4.3 x 3.5 
cm, with no distortion of the endometrial cavity (see figure 6). In addition the 
patients’ symptoms appeared to have completely resolved with her UFS-QOL 
score now 14.  
 
The patient underwent her IVF treatment in January 2008 becoming pregnant 
after the 1st
 
 cycle 10 months post her MRgFUS treatment. No antenatal problems 
were noted at booking. An anomaly scan performed at 20 weeks gestation 
revealed no abnormalities. Serial sonography at 28, 32, 36 and 40 weeks 
demonstrated appropriate fetal growth with cephalic presentation. 
 
 
174 
 
 
Chapter 6 Figure 6: Sagittal view of the pelvis of the same patient (number 
13) 3 months post treatment, showing significant reduction in volume. 
Fibroid now measures 5.1 cm in inferio-superior dimension.  
 
At 39+5 weeks the patient was admitted in spontaneous labour, due to a 
persistently sub-optimal cardiotocograph (CTG) which indicated fetal distress 
despite foetal blood gases within normal levels, the patient was delivered by 
emergency lower uterine segment caesarean section under spinal analgesia. This 
was uncomplicated with a 100ml blood loss reported in the delivery summary 
from her local obstetric unit. A vertex delivery of a healthy male infant weighing 
3050gms was achieved. The cord gases were each of arterial pH of 7.36 and a 
venous pH of 7.28 with a base excess of -1.2 and -1.3.  Apgars at 1 & 5 minutes 
were 9 and 10 respectively. No paediatric follow up was required. 
 
 
Endometrial cavity 
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Discussion 
The complications of untreated leiomyomata in pregnancy are well- known and 
include placental abruption, premature labour and pain from red degeneration 
(Rice, Kay et al. 1989). 
Traditional myomectomy remains the gold standard for fertility preserving fibroid 
treatments. This option remains in favour over newer minimal invasive 
techniques, where there are still concerns regarding the impact on fertility.  
A shift in cultural attitude that is noticeable is that many women no longer find 
surgical treatment of a benign condition acceptable.  
MRgFUS is a non-invasive thermo-ablative technique, which combines the real-
time thermal monitoring capabilities of MRI with the heat-generating properties 
of focused ultrasound waves.  Delivery of concentrated sound energy (sonication) 
heats tissue within the focal area (about 1-2 cm3
 
) to 60-85qC leading to thermal 
injury and subsequent necrosis and apoptosis (Lynn, Zwemer et al. 1942). It is an 
out-patient procedure with minimal sedation requirements and a speedy recovery 
time, allowing patients to return to work within 24 hours, compared to 10 days 
after UAE and 6 weeks with Myomectomy.  
Over 4000 women with symptomatic uterine fibroids have been treated 
worldwide. Published studies have shown that up to 84.6% of women treated, 
experienced significant symptomatic improvement at 24 months post treatment 
follow up (Stewart, Gostout et al. 2007). Initial FDA guidelines recommended 
that only women who had completed their families undergo treatment. However 
with the advantage of consistently good safety and efficacy results being reported, 
multi-centre fertility studies were commenced.  
 
The results from this multi-centre international study are reassuring in that a 
substantial percentage of patients are able to conceive after MRgFUS treatment of 
uterine fibroids, with a spontaneous abortion rate almost similar to the background 
rate at 28%. Most importantly, there were no cases of uterine rupture, pre-term 
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labour, placental abruption, abnormal placentation or fetal growth restriction, with 
a mean birth weight of 3.4Kg (see appendix for international results). MRgFUS 
treatment has the potential to deliver safe and effective treatment for uterine 
fibroid symptoms without damaging patient fertility or creating additional 
pregnancy related risks. Accordingly the Conformitee Europeene (CE) marking 
for the ExAblate system has been changed to include patients wishing to preserve 
their fertility. 
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There is a growing body of data from clinical trials and clinical experience to 
validate the safety and efficacy of MRgFUS for the treatment of uterine fibroids. 
MRgFUS is a totally non-invasive outpatient procedure that is not associated with 
the typical surgical risks of bleeding, infection and has minimal recovery time 
(see figure 1). Additionally, the procedure allows women to address their 
symptoms whilst preserving the uterus.   Consequently, MRgFUS is an alternative 
treatment option for suitable patients who have refused other interventions due to 
concerns about lost productivity, risks of surgical complications or future fertility.  
 
Since uterine fibroids are most common among women during their prime 
working years, the impact of uterine fibroids on productivity is large. In the US it 
has been estimated that 9.9 million employed women suffer from clinically 
diagnosed fibroids (Wu, BirnBaum et al 2006) which implies approximately 2 
million in the UK (Census) It has been suggested that the equivalent of 0.4-0.8 
million work days are lost before surgery (Broder, Landow et al. 2000) and 0.6-
1.4 million work days after surgery in the UK each year. Work absences are 
reported by 40% of women with symptomatic fibroids. 
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Chapter 7 Figure 1: Graph comparing effect of MRgFUS and TAH on 
return to normal activity. 
 
Initial trials of MRgFUS were optimized for safety, and the clinical data from 
these trials demonstrate that the procedure is associated with a very low incidence 
of serious adverse events.   Since MRgFUS was approved in 2004, additional 
trials have evaluated new screening methods or treatment parameters that may 
increase the efficacy of the procedure. For example additional improvements in 
treatment efficacy may be possible with improved selection criteria that better 
identify those UF patients for whom MRgFUS is likely to result in positive 
outcomes. For example our experience seems to suggest that fibroid signal 
intensity on T2-weighted MR images may be predictive of response to MRgFUS, 
with better results seen in fibroids with low or intermediate intensity, therefore by 
pre-treating high intensity fibroids with GnRHa to reduce vascularity we can 
improve treatment outcome. Also by removing restrictions on some margins such 
as desire to preserve fertility, size of fibroids, presence of abdominal scars and 
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allowing for a second treatment session result in a significant increase in the 
percentage of women for whom this treatment may be offered.  
 
A key benefit of MRgFUS is that the procedure allows women to address fibroid 
symptoms while retaining their uterus.  Although initial trials of MRgFUS 
prospectively excluded patients with plans for future fertility, case studies 
demonstrate that conception and delivery of full-term babies is possible after 
undergoing the procedure.  Low birth-weight and stillbirths have not been 
reported in women who have become pregnant following MRgFUS (Rabinovici, 
David et al. 2010). Additional data from treated patients and the comparison of 
pregnancy rates and progression following MRgFUS or myomectomy should 
provide additional insight into fertility capacity following MRgFUS. Ethics 
approval for a RCT comparing myomectomy and MRgFUS has recently been 
applied for and obtained. Patient recruitment is due to start in January 2010. 
 
 
Beyond the benefits associated with a non-invasive treatment for symptomatic 
uterine fibroids, a cost effectiveness analysis performed at the London school of 
Hygiene and Tropical Medicine evaluated the cost-effectiveness of adding 
MRgFUS to the arsenal of existing treatments for uterine fibroids. The results of 
this study suggested that a treatment strategy starting with MRgFUS is potentially 
more effective and less costly than current practice, however the cost per quality 
adjusted life year gained is sensitive to the cost of MRgFUS relative to other 
treatments, the age of the woman and the non-perfused volume relative to the total 
fibroids volume (Zowall, Cairns et al. 2008). 
 
As an outpatient therapy, MRgFUS offers insurers reduced treatment costs. 
Additionally, the ability to offer patients a non-invasive treatment alternative may 
help hospitals attract uterine fibroid patients to their facilities. An internal review 
of fibroid treatments at our institution before and after introduction of an 
MRgFUS service indicated an increase in all fibroid treatment modalities. (see 
table below). 
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Year 2001 2006 
Hysterectomy (fibroids only) 76 32 
Myomectomy 45 79 
UAE 11 175 
FUS n/a 73 
 
Chapter 7 table 1: Comparison of treatment modality numbers pre and 
post introduction of MRgFUS in our unit. 
 
In summary, MRgFUS appears to be a safe and effective approach to treating 
symptomatic uterine fibroids.  The non-invasive procedure offers women a 
therapeutic option that avoids the potential risks and lengthy recover periods 
associated with hysterectomy, myomectomy and UAE.  Early data suggest that 
MRgFUS is compatible with subsequent fertility and ongoing trials should help to 
clarify pregnancy rates, progression and risks following the procedure.   
 
Continued clinical evaluation and experience should enable further refinement of 
patient selection and treatment parameters, resulting in improved efficacy.  A 
retrospective review is currently underway aimed at identifying the percentage of 
targeted fibroid required to be treated for symptom maintenance at 12 months post 
treatment. A current figure of 40% non-perfusion post–treatment has been set by 
the manufacturer, however A UAE procedure is deemed successful only if there is 
>85% of non-perfusion achieved. By analysing retrospectively patients QOL 
scores at 12 months and correlating this with NPV percentages achieved post-
treatment, we can determine what percentage of ablation is required to be created 
to ensure long-term maintenance of symptom improvement. 
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Patient Number: _______ Patient Initials: _________ 
Date:  __________      Visit _______________________
  
 
UTERINE FIBROID SYMPTOM AND HEALTH-RELATED QUALITY OF 
LIFE QUESTIONNAIRE (UFS-QOL) 
 
 
 
Listed below are symptoms experienced by women who have uterine fibroids.  Please consider each 
symptom as it relates to your uterine fibroids or menstrual cycle.  Each question asks how much distress 
you have experienced from each symptom during the previous 3 months. 
 
There are no right or wrong answers.  Please be sure to answer every question by checking (9) the most 
appropriate box.  If a question does not apply to you, please mark "not at all" as a response. 
 
During the previous 3 months, how distressed 
were you by… 
Not at 
all 
A little 
bit 
Some- 
what 
A great 
deal 
A very 
great 
deal 
1.   Heavy bleeding during your menstrual period 1 2 3 4 5 
2.   Passing blood clots during your menstrual period 1 2 3 4 5 
3.   Fluctuation in the duration of your menstrual 
period compared to your previous cycles 1 2 3 4 5 
4.   Fluctuation in the length of your monthly cycle 
compared to your previous cycles 1 2 3 4 5 
5.   Feeling tightness or pressure in your pelvic area 1 2 3 4 5 
6.   Frequent urination during the daytime hours 1 2 3 4 5 
7.   Frequent nighttime urination 1 2 3 4 5 
8.   Feeling fatigued 1 2 3 4 5 
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The following questions ask about your feelings and experiences regarding the impact of 
uterine fibroid symptoms on your life.  Please consider each question as it relates to your 
experiences with uterine fibroids during the previous 3 months. 
 
There are no right or wrong answers.  Please be sure to answer every question by checking  
(9) the most appropriate box.  If the question does not apply to you, please check "none  
of the time" as your option. 
 
During the previous 3 months, how often have 
your symptoms related to uterine fibroids... 
None of 
the  
time 
A little 
of the 
time 
Some  
of the  
time 
Most  
of the 
time 
All of 
the  
time 
9.   Made you feel anxious about the 
unpredictable onset or duration of your 
periods? 1 2 3 4 5 
10. Made you anxious about traveling? 1 2 3 4 5 
11. Interfered with your physical activities? 1 2 3 4 5 
12. Caused you to feel tired or worn out? 1 2 3 4 5 
13. Made you decrease the amount of time you 
spent on exercise or other physical activities? 1 2 3 4 5 
14. Made you feel as if you are not in control of 
your life? 1 2 3 4 5 
15. Made you concerned about soiling 
underclothes? 1 2 3 4 5 
16. Made you feel less productive? 1 2 3 4 5 
17. Caused you to feel drowsy or sleepy during 
the day? 1 2 3 4 5 
18.  Made you feel self-conscious of weight 
gain? 1 2 3 4 5 
19. Made you feel that it was difficult to carry 
out your usual activities? 1 2 3 4 5 
20. Interfered with your social activities? 1 2 3 4 5 
21. Made you feel conscious about the size and 
appearance of your stomach? 1 2 3 4 5 
22. Made you concerned about soiling bed linen? 1 2 3 4 5 
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During the previous 3 months, how often have 
your symptoms related to uterine fibroids... 
None of 
the  
time 
A little 
of the 
time 
Some of 
the  
time 
Most of 
the time 
All of 
the  
time 
23. Made you feel sad, discouraged, or hopeless? 1 2 3 4 5 
24. Made you feel down hearted and blue? 1 2 3 4 5 
25. Made you feel wiped out? 1 2 3 4 5 
26. Caused you to be concerned or worried about 
your health? 1 2 3 4 5 
27. Caused you to plan activities more carefully? 1 2 3 4 5 
28. Made you feel inconvenienced about always 
carrying extra pads, tampons, and clothing to 
avoid accidents? 1 2 3 4 5 
29. Caused you embarrassment? 1 2 3 4 5 
30. Made you feel uncertain about your future? 1 2 3 4 5 
31. Made you feel irritable? 1 2 3 4 5 
32. Made you concerned about soiling outer 
clothes? 1 2 3 4 5 
33. Affected the size of clothing you wear during 
your periods? 1 2 3 4 5 
34. Made you feel that you are not in control of 
your health? 1 2 3 4 5 
35. Made you feel weak as if energy was drained 
from your body? 1 2 3 4 5 
36. Diminished your sexual desire? 1 2 3 4 5 
37. Caused you to avoid sexual relations? 1 2 3 4 5 
 
 
MR GUIDED FOCUSED ULTRASOUND SURGERY IN THE TREATMENT OF UTERINE FIBROIDS FOLLOWING GNRH 
TREATMENT 
 
PRINCIPAL INVESTIGATOR: 
 
SUBJECT'S INITIALS: 
 
 
 
SUBJECT NUMBER: 
 
UF004- 
 
DATE OF VISIT: 
 
______/______/_____ 
             dd        mm       yy 
ENROLLMENT FORM 
 
 
 Page 1 of 2  
Directions: Review the INCLUSION AND EXCLUSION CRITERIA below to determine the patient’s 
eligibility for entry into the study 
 
PATIENT INCLUSION CRITERIA (3 Yes if present, No if not present) Yes No 
1. Patient has given consent   
2. Patient is willing and able to attend all study    
     3. Patient is a female of at least 18 years of age with a symptomatic uterine fibroid(s)  
     who has completed her    
4. Patient presents with a uterine fibroid size of more than 300cc    
5. Clinically normal Pap smear within timing of national guidelines    
6. Raw score of 21 or greater on the UFS-QOL  symptom severity screener.   
7. Patient is pre or peri-menopausal (within 12 months of last menstrual period).   
8. Patient is able to communicate sensations during the MRgFUS procedure.   
9. Uterine fibroids which are device accessible    
10. Tumour(s) clearly visible on no-contrast MRI   
11. The use or non-use of non-steroidal treatments for excessive vaginal bleeding 
such as anti-fibrinolytic agents (e.g. Tranexamic acid) or non-steroidal anti-
inflammatory drugs (e.g. Mefenamic acid) should remain constant from three months 
pre-study and throughout the follow-up period. 
  
 
A No answer to any of the above Inclusion Criteria disqualifies a patient from entry into the study. 
   
PATIENT EXCLUSION CRITERIA (3 Yes if present, No if not present) Yes No 
1. Patient is pregnant as confirmed by pregnancy test at time of screening    
2. patient has had previous GnRH treatment   
3. Patient using hormone replacement therapy   
4. Patient using hormonal contraception   
5. Patient on dialysis   
6. Hematocrit is < 25   
7. Patient has hemolytic anemia   
 
MR GUIDED FOCUSED ULTRASOUND SURGERY IN THE TREATMENT OF UTERINE FIBROIDS FOLLOWING GNRH 
TREATMENT 
 
PRINCIPAL INVESTIGATOR: 
 
SUBJECT'S INITIALS: 
 
 
 
SUBJECT NUMBER: 
 
UF004- 
 
DATE OF VISIT: 
 
______/______/_____ 
             dd        mm       yy 
ENROLLMENT FORM 
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PATIENT EXCLUSION CRITERIA (3 Yes if present, No if not present) Yes No 
8. Patient has unstable cardiac status including:  
 Unstable angina pectoris on medication 
 Documented myocardial infarction within 6 months of protocol entry 
 Congestive heart failure requiring medication (other than diuretic) 
 Currently taking anti-arrhythmic drugs 
 Severe hypertension (diastolic BP>100 on medication) 
 Presence of cardiac pacemaker   
  
9. Patient has an ASA score of >2    
10. Patient has severe cerebrovascular disease (multiple CVA or CVA within 6 months)   
11. Patient is on anti-coagulation therapy or has an underlying bleeding disorder    
12. Evidence of uterine pathology other than leiomyoma   
13. Patient has an active pelvic infection or history of pelvic inflammatory disease   
14. Patient has an undiagnosed pelvic mass outside the uterus.   
15. Patient weight >110 kg   
16. Subject with extensive abdominal scarring in an area of the abdomen directly anterior 
to the treatment area.   
17. Subject with standard contraindications for MR imaging such as non-MRI compatable 
implanted metallic devices.    
18. Known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist).   
19. Individuals who are not able or willing to tolerate the required prolonged stationary 
prone position during treatment (approximately 3 hours.)    
20. Patient with an intrauterine contraceptive device anywhere in the treatment beam 
path.   
21. Women who are breast feeding.   
A Yes answer to any of the above Exclusion Criteria disqualifies a patient from entry into the 
study. 
IF PATIENT HAS MET ALL INCLUSION/EXCLUSION CRITERIA AND SIGNED THE CONSENT FORM, THEN 
SCHEDULE FUS TREATMENT. 
IF PATIENT DOES NOT MEET ALL THE INCLUSION AND EXCLUSION CRITERIA BUT YOU WISH TO ENTER 
THE PATIENT INTO THE STUDY, CONTACT InSightec BEFORE PROCEEDING. 
 
 ____________________________________________   _________________________  
  Investigator’s Signature    Date 
 
MR GUIDED FOCUSED ULTRASOUND SURGERY IN THE TREATMENT OF UTERINE FIBROIDS IN WOMEN DESIRING 
FUTURE PREGNANCIES 
 
PRINCIPAL INVESTIGATOR: 
 
SUBJECT'S INITIALS: 
 
 
 
SUBJECT NUMBER: 
 
UF004- 
 
DATE OF VISIT: 
 
______/______/_____ 
             dd        mm       yy 
ENROLLMENT FORM 
 
 
 Page 1 of 2  
Directions: Review the INCLUSION AND EXCLUSION CRITERIA below to determine the patient’s 
eligibility for entry into the study 
 
PATIENT INCLUSION CRITERIA (3 Yes if present, No if not present) Yes No 
1. Subject with uterine fibroids, who desire pregnancy within 12 months and has the one 
of the following criteria: 
x Women 20-40 age. 
x Women age < 46 years old who plan to have egg donation. 
x Women above 38 should test for normal ovarian function as judged by 
endocrinological evaluation. 
x If the couple has failed to conceive for more that 1 year, the woman should test for 
normal ovarian function as judged by endocrinological evaluation, and the male 
must have adequate sperm test. 
x Women undergoing fertility treatment or plan to have sperm donation. 
  
2. Use or non use of non-steroidal treatments for excessive vaginal bleeding such as 
antifibrinolytic agents (e.g. Tranexamic acid) or non-steroidal anti-inflammatory drugs 
(e.g. Mefanamic Acid) has been maintained for the three months prior to the planned 
date of the study procedure and the patient has agreed to maintain this use or non-
use through the 6-month follow-up period. 
  
3. Clinically normal PAP smear within timing of National Guidelines in the country of the 
clinical site.   
4. Able and willing to give consent and able to attend all study visits   
5. Able to communicate sensations during the MRgFUS procedure   
6. Having uterine fibroids that are device accessible (i.e., positioned in the uterus such 
that they can be accessed without being shielded by bowel or bone).   
7. Tumor(s) are clearly visible on non-contrast MRI.   
8. Largest fibroid 8 cm in diameter or 12 cm if receiving GnRH   
 
A No answer to any of the above Inclusion Criteria disqualifies a patient from entry into the study. 
   
PATIENT EXCLUSION CRITERIA (3 Yes if present, No if not present) Yes No 
1. Patient is pregnant as confirmed by pregnancy test at time of screening    
2. Uterine size !20 weeks as evaluated by US or MR.   
3. Patients who are considered “high risk pregnancy” due to uterine factors (e.g. 
abnormal uterus, uterine scars, cerclage) except fibroids.   
4. Patients with fibroid that is more than 50% sub-mucosal or with hysteroscopically 
resectable   
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SUBJECT NUMBER: 
 
UF004- 
 
DATE OF VISIT: 
 
______/______/_____ 
             dd        mm       yy 
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PATIENT EXCLUSION CRITERIA (3 Yes if present, No if not present) Yes No 
5. Patients with adenomyosis   
6. Patient is on dialysis   
7. Hematocrit is < 25   
8. Patient has hemolytic anemia   
9. Patient has unstable cardiac status including:  
 Unstable angina pectoris on medication 
 Documented myocardial infarction within 6 months of protocol entry 
 Congestive heart failure requiring medication (other than diuretic) 
 Currently taking anti-arrhythmic drugs 
 Severe hypertension (diastolic BP>100 on medication) 
 Presence of cardiac pacemaker   
  
10. Patient has an ASA score of >2    
11. Patient has severe cerebrovascular disease (multiple CVA or CVA within 6 months)   
12. Patient is on anti-coagulation therapy or has an underlying bleeding disorder    
13. Evidence of uterine pathology other than leiomyoma   
14. Patient has an active pelvic infection or history of pelvic inflammatory disease   
15. Patient has an undiagnosed pelvic mass outside the uterus.   
16. Patient weight >110 kg   
17. Subject with extensive abdominal scarring in an area of the abdomen directly anterior 
to the treatment area.   
18. Subject with standard contraindications for MR imaging such as non-MRI compatable 
implanted metallic devices.    
19. Known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist).   
20. Individuals who are not able or willing to tolerate the required prolonged stationary 
prone position during treatment (approximately 3 hours.)    
21. Patient with an intrauterine contraceptive device anywhere in the treatment beam 
path.   
22. Women who are breast feeding.   
23. Five or more fibroids, bigger then 3cm diameter, each   
A Yes answer to any of the above Exclusion Criteria disqualifies a patient from entry into the 
study. 
IF PATIENT HAS MET ALL INCLUSION/EXCLUSION CRITERIA AND SIGNED THE CONSENT FORM, THEN 
SCHEDULE FUS TREATMENT. 
IF PATIENT DOES NOT MEET ALL THE INCLUSION AND EXCLUSION CRITERIA BUT YOU WISH TO ENTER 
THE PATIENT INTO THE STUDY, CONTACT InSightec BEFORE PROCEEDING. 
 
 ____________________________________________   _________________________  
  Investigator’s Signature    Date 
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Delivery Complications um Complications (mwborn Complicatio
Age (at 
first tx) Race
# of 
previous 
pregnancie
s
# of 
previous 
deliveries
Prior 
infertility 
history
QOL-SSS 
prior to treat 
(0-100)
Volume of 
all fibroids 
(cc)
Treated 
fibroids 
location
Complications during 
pregnancy
Pregnancy 
outcome
Gestational 
age
 (at 
outcome) 
Baby 
gender
Baby 
weight 
(gr)
APGAR 
score
Delivery 
Complication
Postpartum 
Complications 
(maternal)
Newborn 
Complications
1
St. Mary's, 
England UF008-
520
41 white 2 0 Yes 84 279 Intramural Early pregnancy bleeding Miscarriage Week 10 - - - None
2
Charite, 
Germany 
UF004-804
40 white 1 0 Yes 53 21 intramural Bleeding during weeks 8 and 9 Vaginal Week 42 Male 3870 10,10 None None None
34 white 2 0 Yes 11 43 intramural None till miscarriage, bleeding Miscarriage Week 9 - - -
bleeding every 2-3 weeks 
during the first 3-4 months 
of pregnancy
Vaginal week 40 Male 3830 8,9 None
4
Charite, 
Germany 
UF004-814
34 white 1 0 UNK 60 65 intramural Chlamydia Caesarean Week 38 Female 3480 None None None
5 Sheba, Israel UF002-612 44 white 3 1 UNK 69 293
2 intramural, 1 
subserosal
None MA 8W + D&C Week 8 - - - None
6 Sheba, Israel UF004-602 36 white 2 1 Yes 41 84 Focal fundi
suspected diagnosis of 
persistent right umbilical 
vein
Vaginal UNK Female 3050 UNK
Placenta residual that 
needed REVISIO (physical 
examination of the uterus for 
placenta residuals)
28 african 4 4 Yes 34 230 submucosal 
IUI (Intra Uterine 
insemination)            Week 
35 hospitalized due to 
PMC (premature 
contractions) and lumbar 
Caesarean Week 38 Male 2656 9,10
due to fetus positioning 
caesarean surgery scheduled. 
During surgery also underwent 
myomectomy. 3 hrs post 
surgery patient started to bleed 
l  d h d DIC  Pt  
After C/S, OK 
ARDS, SAE 
reported
None
250 2 submucosal, 1 Subserosal 
Early pregnancy bleeding 
in the beginning of the 
pregnancy, and 
hospitalization at weeks 28-
30 due to bleedings 
(caused by placenta 
previa)
Caesarean week 39 Male 2860 9,10
Reason for cesarian surgery 
is complicated uterine scar 
and placenta previa. 
Respiratory problems lasted 
several days post delivery. 
Reffered to respiratory unit, 
with no specific findings.
32 white 2 1 None 94 73 intermural/ submocosal 
10th week heavy bleeding – 
refered for D&C Miscarriage Week 10 - - - Hyteroscopy
9th week found that the fetus 
has no pulse. Performed 
D&C.
Miscarriage Week 9 - - -
9
ShinSuma, 
Japan UF007-
73003
30 Japanese 0 0 UNK UNK 200 Intramural bleeding and FHM(-) Miscarriage Week 7 - - -
10
ShinSuma, 
Japan UF007-
73035
41 Japanese 0 0 UNK UNK 950 Intramural
Patient had the FUS Tx 
after her last ovulation and 
before her next period
Abortion - - - -
36 Japanese 1 0 UNK UNK 740 Intramural Temporary sign of miscarriage (bleeding) Caesarean
week 41 
+5/7
Female 3966 8,9
740 1 subserosal 1 intramural 
Medical history
No. Pt. ID
Demographics
3
Charite, 
Germany 
UF004-805
Sheba, Israel 
UF004-6067
11
8 Sheba, Israel   UF004-616
ShinSuma, 
Japan UF007-
73044/8
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12 Itabashi, Japan UF007-74033 29 Japanese 0 0 UNK UNK 215  subserosal None Vaginal week 39 male 3212 8,9 none
13 IseiKei, Japan UF007-71095 33 Japanese 0 0 None UNK 281 Intramural UNK Miscarriage
Week 
8-10 (est) - - -
14 BWH, USA UF005-2172 40 white 3 3 Yes 72 396
1 submocosal 
1 intramural
Patient experienced first-
trimester vaginal bleeding 
until 16 weeks of gestation, 
and was diagnosed with 
diabetes mellitus type II. 
Vaginal week 39 +0/7 Male 3170 5.1/9.5 None
Moderate to heavy 
lochia None
15 BWH, USA UF005-2175 44 white 0 0 None 47 480 intramural Gestational diabetes Vaginal week 40 Male 3345 7, 8 Chorioamnionitis None None
16 BWH, USA UF005-2176 42 white 2 2 None 50 179 submucosal
None Caesarean Week 38-4/7
Female 3425 8,8 None None
baby was in the 
NICU for a 
couple days 
after the birth 
because she 
had a lung 
17 Mayo, USA UF005-04105 40 white 0 0 None 72 377 subserosal
gestational diabetes, 
hypertension Vaginal Week 40
Female 3600 9@1&5 None None None
18 Itabashi, Japan UF007-74072 42 Japanese 0 0 UNK UNK 333 Intramural None Abortion Week 7
41 other 1 0 UNK 59 606 intramural None Miscarriage Week 13 None
606 intramural
20
Roszdrav, 
Russia UF007-
51015
31 white 1 0 UNK UNK 650 3 intramural, 1 subserosal None Abortion Week 6-7
21
Roszdrav, 
Russia UF007-
51016
42 white 0 0 None UNK 216 submucosal
retrochorial haematoma 
because of multi-fibroid 
uterus
Miscarriage week 12-13
22
ShinSuma, 
Japan AD002-
7306
32 Japanese 3 2 none 44 370 Adenomyosis None Abortion Week 11
23 Itabashi, Japan UF007-74147 42 Japanese 0 0 UNK UNK 600 intramural None Abortion Week 7
24
Sightline, 
Huston UF007-
3413
39 white 0 0 none UNK 423 subserosal
Decreased amniotic fluid 
volume, placental 
insufficiency
Vaginal week 38-5 girl 2892 9
Pt was 
hospitalized for 
puerperal 
endometritis
25 Itabashi, Japan UF007-74075 36 Japanese 2 1 None UNK 249 Intramural None Caesarean week 37-4 girl 2992 10
Pt had myomectomy during 
the delivery
26
Sightline, 
Huston UF007-
34-060926
45 white 1 0
yes
UNK 210 intramural
Trisomy 14 chromosomal 
abnormality and the related 
physical abnormalities in 
the fetus are the likely the 
reason for the loss
Miscarriage Week 8-10
27 Amour UF007-75033 36 Japanese 1 0 yes N/A 98 intramural LTF
19
St. Mary's, 
England UF008-
518
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35 white 4 3 None 47 488 submucosal
at week 20 arrived to ER 
with pain, fetus had no 
pulse. Underwent D&C
Premature labor week 20 None
343 submucosal
31 Asian 0 0 None 53 173 Intramural Vaginal week39+1 girl 3190
163 Intramural
30 St. Mary's UF004-531 35 african 1 0 No 54 340 intramural None Vaginal 42 girl 3580@1, 9@10, 9@None None None
31 Korea UF007-81110 39 Asian 2 1 Yes 22 75 submucosal Caesarean week 38 boy 3400 None None None
41 White 1 1 Geslosis? 297 submucosal
Myoma growth during 21st 
week of pregnancy lead to 
myomectomy
Caesarean week 36 girl 3410 Placenta previa None None
233 submucosal, intramural
33
Charite, 
Germany 
UF004-842
36 White No 1 UNK None Vaginal
UNK
boy 3760 None None None
35 white No UNK UNK None Vaginal boy 3100 None None None
65 intramural
37 white 0 0 No 9.375 63.5 Intramural None Miscarriage Week 4 None
31.8 Intramural
36
Charite, 
Germany 
UF004-854
40 white 4 2 Yes 160 Transmural small myoma growth, size 9    Vaginal UNK girl 3190 None None None
33 white 1 0 Yes 13 124 subserosal None LTF
UNK UNK
41 white 0 0 None 34
350 trans
Gestational Diabetes, 
abdominal pain, anemia Caesarean week 38 boy 3100 9 @ 10 none none none
314 trans
39
Korea UF007-
81060 41
Asian
1 1 None 41
226 subserosal
none
Abortion
Week 6
40
Korea UF007-
81137 32
Asian
0 0 Yes 21
99 submucosal
none reported
vaginal
week 40+4 boy 3200
41
Bochum UF007-
73006 31
White
0 0 Yes N/A
178 Intramural Caesarean
girl 3010
42
Roszdrav, 
Russia UF007-
51004 37
White
1 1 UNK
52 Intramural
weeks 5&10 bleeding. 
Week 14-15: 
hospitalization due to risk 
for miscarrige
vaginal
girl
43 Sheba, UF004-630 41
White
4 2
283 intramural
none
Miscarriage
Week 9 None
33
White
2 0
227 intramural ongoing
29 Korea UF007-81015
32
Charite, 
Germany 
UF004-837
Charite, 
Germany 
UF004-858
Charite, 
Germany 
UF004-848
35
Sheba UF004-
62528
Roszdrav, 
Russia UF007-
Charite, 
Germany 
UF004-849
Sheba, Israel 
UF004-62438
34
37
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248 UNK
45
Roszdrav, 
Russia UF007-
51138
34
White
5 1
248 transmural
None
Caesarean
week 40 boy 3680
46
Roszdrav, 
Russia UF007-
51062
49
White
4 0 yes
513
submucosal, 
intramural, 
pedunculated
ongoing
47
Roszdrav, 
Russia UF007-
51-071227
39
White
4 3
59 intramural
check translation
Ongoing
48
Roszdrav, 
Russia UF007-
51-070629 34
White
1 0 yes
61 intramural Miscarriage
49
Sightline 
Houston UF007-
34-070524 38
Hispanic
3 1 No
111 submucosal, subserosal None
vaginal
40 weeks male 3202 7,9 none none none
34 White UNK UNK 22.5 submucosal None delivered none
22.5 submucosal
51
Roszdrav, 
Russia UF007-
51161
40 white 0 0 34 intramural, submucosal miscarriage
52 Atlanta UF007-38-080424 30 white 0 0 yes miscarriage
53 Roszdrav 42 abortion
Charite, 
Germany 
UF004-846
33 white 0 0 No
had some pain, was unable 
to work sometimes, no 
hospitalization
vaginal male 2690 UNK None
27 intramural
55 Korea 12cm
56 Centre for 
Family Planning
57
Sheba UF004-
629
40 white yes
Pt. was hospitalized due to 
bleeding. After initial 
diagnosis, Pt. received 
Methtrexat and miscarriage miscarriage 
58 Sightline, 
Atlanta UF007-
38-080904
37 3 2 no 284 intramural
miscarriage 
59
St. Mary's
46 white 4 0 yes sub-mucosal
none Caesarean
week 40 male emergency c-section for fetal distress
60
CEMEDI
39 28 intramural
50
Charite, 
Germany 
UF004-853
54
44
 
Russia UF007-
51-070523
